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Abstract
The vector-borne diseases Leishmaniasis and Chagas disease, caused by the kinetoplastid
parasites Leishmania spp. and Trypanosoma cruzi respectively, are among the most important
parasitic diseases in the group of neglected tropical diseases. Even though the two diseases are
endemic to the Americas, they affect millions of people worldwide. Leishmaniasis and Chagas
disease cause a great array of symptoms and some of them can be fatal if left undiagnosed and
untreated. Current treatment regimens are becoming less effective, vaccines are still not available,
and diagnosis needs to be improved. Vector control has been responsible for a decrease of diseases
in endemic areas. However, in non-endemic areas, vector control strategies are nonexistent due to
an inadequate understanding of vector epidemiology and without proper monitoring and evaluation
of vector and associated parasite. Therefore, there is an urgent need to evaluate different strategies
for the treatment, diagnosis and prevention (vaccine prevention and vector control) of
Leishmaniasis and Chagas disease.
In this regard, the first part of this study, we evaluated two types of compounds, thiophene
derivatives and methionine aminopeptidase 1 (MetAP1 inhibitors), for the treatment of cutaneous
leishmaniasis, one of the clinical manifestations of leishmaniasis, caused by Leishmania major.
The first class of compounds, thiophene derivatives, were synthesized and evaluated their parasitic
activity, and potential mechanism of action (MOA). We developed a structure–activity relationship
(SAR) study of the thiophene molecule 5A. Overall, eight thiophene derivatives of 5A were
synthesized and purified by silica gel column chromatography. Of these eight analogs, the
molecule 5D showed the highest in vitro activity against Leishmania major promastigotes (EC50
0.09 ± 0.02 μM), with an inhibition of the proliferation of intracellular amastigotes higher than
75% at only 0.63 μM and an excellent selective index. Moreover, the effect of 5D on L. major
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promastigotes was associated with generation of reactive oxygen species (ROS), and in silico
docking studies suggested that 5D may play a role in inhibiting trypanothione reductase. In
summary, the combined SAR study and the in vitro evaluation of 5A derivatives allowed the
identification of the novel molecule 5D, which exhibited potent in vitro anti-leishmanial activity
resulting in ROS production leading to cell death with no significant cytotoxicity towards
mammalian cells. The second class of compounds, MetAP1 inhibitors, were validated as a
chemotherapeutic target against CL infection. The in vitro antileishmanial activities of eight novel
MetAP1 inhibitors (OJT001 to OJT008) were investigated. Three compounds, OJT006, OJT007,
and OJT008, demonstrated potent antiproliferative effects in macrophages infected with L. major
amastigotes and promastigotes at submicromolar concentrations, with no cytotoxicity against host
cells. Importantly, the leishmanicidal effect in transgenic L. major promastigotes overexpressing
MetAP1Lm was diminished by almost 10-fold in comparison to the effect in wild-type
promastigotes. Furthermore, the in vivo activities of OJT006, OJT007, and OJT008 were
investigated in L. major-infected BALB/c mice. In comparison to the footpad parasite load in the
control group, OJT008 decreased the footpad parasite load significantly, by 86%, and exhibited no
toxicity in treated mice. We propose thiophene derivative 5D and MetAP1 inhibitor OJT008 as
potential chemotherapeutic candidates against CL infection caused by L. major.
The second part, we aim to identify and characterized glycosylphosphatidylinositolanchored proteins (GPI-AP) that display highly immunogenic terminal nonreducing αgalactopyranosyl (α-Gal)- containing glycotopes that can be used as biomarker and vaccine
candidates. Here, GPI-AP were extracted from promastigotes (PR) and metacyclic promastigotes
(MP) of L. major, L. braziliensis and L. guyanensis, and L. donovani which cause CL, MCL and
VL respectively and analyzed by CL-ELISA, western blot and mass spectrometry. α-Gal
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containing GPI-AP were isolated by lectin affinity chromatography (LAC) with immobilized
Bandeiraea simplicifolia isolectin 4 (IB4) and further fractionated by hydrophobic interaction
chromatography with an octyl-Sepharose column (HIC-OS) in a propanol gradient. Results
indicated the presence of α-Gal containing GPI-AP in L. major and two strain of L. braziliensis in
both stages, PR and MP. Further analysis is needed to fully characterize α -gal containing GPI-AP
in each Leishmania sample. Moreover, a ~33 kDa glycoprotein was found by western blot probed
with IB4 and serum from CL patients. This glycoprotein needs to be further characterized by mass
spectrometry and be tested as biomarker.
The third and final part of this study, vector surveillance and epidemiology were
implemented in the Southwestern region of U.S. where epidemiological studies are limited. We
have determined the prevalence of T. cruzi in triatomines, feral cats and dogs, and wild animals,
as well as the infecting parasite genotypes and the mammalian host bloodmeal sources of the
triatomines at four different geographical sites in the U.S.-Mexico border, including El Paso
County, Texas, and nearby cities in New Mexico. Using qualitative polymerase chain reaction to
detect T. cruzi infections, we found 66.4% (n=225) of triatomines, 45.3% (n=95) of feral dogs,
39.2% (n=24) of feral cats, and 71.4% (n=7) of wild animals positive for T. cruzi. Over 95% of T.
cruzi genotypes or discrete typing units (DTUs) identified were TcI and some TcIV. Furthermore,
Triatoma rubida was the triatomine species most frequently (98.2%) collected in all samples
analyzed. These findings suggest a high prevalence of T. cruzi infections among triatomines, and
feral and wild animals in the studied sites. Therefore, our results underscore the urgent need for
implementation of a systematic epidemiological surveillance program for T. cruzi infections in
insect vectors, and feral and wild animals, and Chagas disease in the human population in the
southwestern region of the United States.
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Chapter 1: General Introduction
1.1 LEISHMANIASIS AND LEISHMANIA SP.
Leishmaniasis is a vector-borne disease caused by parasites of the genus Leishmania.
Leishmania parasites are transmitted to vertebrates by the bite of an infected female sand fly
(Phlebotomus or Lutzomyia sand fly in Old and New Worlds, respectively), and are frequently
hosted by canids, rodents, marsupials, bats, and human beings. There are around 350 million
people worldwide at risk of acquiring leishmaniasis and 12 million current cases with an annual
incidence of 2 million new cases (1). The disease is endemic in large areas of the tropics, subtropics
and the Mediterranean, spanning more than 98 countries, many of which have two or more
Leishmania sp. present and are mostly sympatric making it a growing public health for several
countries (Fig. 1.1) (1, 2). Currently, 54 Leishmania species are known and at least 21 of them are
pathogenic to humans causing three major clinical manifestations: cutaneous leishmaniasis (CL),
mucocutaneous leishmaniasis (MCL) and visceral leishmaniasis (VL) (Fig. 1.2) (3).

Figure 1.1 Global distribution of 21 Leishmania species pathogenic for humans. The species
name has been shown as abbreviation. A: L. aethiopica; Am: L. amazonensis; B: L. braziliensis;
C: L. colombiensis; D: L. donovani; G: L. guyanensis; Gh: ‘Ghana strain’; I: L. infantum; La: L.
lainsoni; L: L. lindenbergi; M: L. major; Ma: L. martiniquensis; Mx: L. mexicana; N: L. naiffi; Pa:
1

L. panamensis; P: L. peruviana; S: L. ‘siamensis’; Sh: L. shawi; T: L. tropica; V: L. venezuelensis
and W: L. waltoni. Adapted from Akhoundi et al. 2017.

Figure 1.2 Classification of Leishmania species.*, +: Synonym; different numbers of star (*) and
plus (+) signs mean which species name is the synonym for which original species, Underlined:
No final classification. L. ‘siamensis’ and L. martiniquensis have been found also in the New
World. Leishmania names in quotation mark are unofficial names without formal descriptions.
The human pathogenic species are written in bold. Old and New world species are highlighted in
blue and red respectively. Adapted from Akhoundi et al. 2017.
CL is the most common form of the disease with an annual estimate of 0.7 to 1.2 million
cases (1). The disease causes localized or diffused skin ulcers, causing social prejudice due to the
formation of exposed skin lesions. Lesions can self-heal in several months (3-5 months) or undergo
slow healing (15-20 years) leading to permanent scaring in patients (4). Old World CL is mainly
transmitted by L. major or L. tropica in the Middle East, Southern Europe, Southwest Asia and
Africa; and L. mexicana and L. amazonensis in the New World (Central and South America) (5).
2

MCL is another form of the disease that affect the mucosal membranes, developing disfiguring
and destructive lesions that usually start appearing in nasal mucosa, spreading to the pharynx, oral
mucosa, and the larynx (6). MCL only occurs in the New World, and it is mainly caused by L.
braziliensis and L. panamensis (2). Finally, VL is the most severe form of the disease that can be
fatal if untreated (7). Symptoms include fever, splenomegaly, hepatomegaly, progressive anemia,
and extreme weight loss (8). VL is caused by L. donovani and L. infantum in the Old World and
L. chagasi in the New World (8). A summary of the clinical forms and the species that cause them
is presented in Figure 1.3

Figure 1.3. Different Leishmania species causing various clinical manifestation of leishmaniasis
The color range demonstrates the relative nearness of Leishmania species to each clinical
manifestation based on the frequency of clinical disease cases. Adapted from Akhoundi et al. 2017.
Leishmania develop as flagellated promastigotes in the digestive tract of the sandfly vector.
Parasites taken up with a bloodmeal differentiate into rapidly dividing promastigotes, which
subsequently pass through several distinct physiological and morphological transitions before
3

differentiating into a the highly motile, non-dividing ‘metacyclic’ stage. Metacyclic promastigotes
are injected into the skin of the mammalian host during the sandfly bloodmeal and are likely to be
the major developmental form responsible for initiating infection in macrophages. Metacyclic
promastigotes are highly resistant to complement lysis and rapidly invade macrophages recruited
to the site of the sandfly bite. After internalization into the phagolysosome compartment, they
differentiate to small, non-motile amastigotes that proliferate within the macrophage
phagolysosome. Amastigotes perpetuate disease in the mammalian host as a result of continuous
release due to macrophage lysis and invasion of other macrophages (Fig 1.4)

Figure 1.4 Life cycle of Leishmania sp. Adapted from Handman 2001
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1.1.1

Current treatments for leishmaniasis
Effective treatment against leishmaniasis include three parental agents: pentavalent

antimonies in the form of sodium stibogluconate (Pentostam) or meglumine antimoniate
(Glucantime), and liposomal amphotericin B, and three oral agents, miltefosine and the azoles,
fluconazole and ketoconazole. Each of these agents has its own individual advantages and
drawbacks. There are many important factors which play a role in the initial consideration of
treatment, including the geographic region where infection was acquired, the species of
Leishmania involved (to where diagnosis play a critical role), and the extent and location lesions.
Pentavalent antimonials [Sb(V)] were developed more than 60 years ago and still remains the most
standard treatment for all clinical forms(9). Although antimonials present several advantages such
as low cost and high efficacy for VL (35-90%), and CL (25-100%), these drugs exhibit side effects
such as anorexia, nausea, vomiting, increase in hepatic enzymes, tachycardia, and severe to fatal
arrhythmias (10). Another disadvantage is the administration and long treatment periods of
antimonials where patients have difficulty tolerating the full IV treatment course (11). For instance,
administration can be either by intravenous infusions or intramuscular injections at 20 mg/kg for
20-38 days for VL; and intralesional treatment with 5 separate doses every 5-7 days, or
systemically at 20 mg/kg for 20 days in the case of CL (4).Furthermore, in Bihar, India around
1980’s, antimonials started to be ineffective in relapsed patients with VL (12). Its efficacy
decreased by a 65%, mainly because the widespread misuse of the drug, and the emergence of
Leishmania antimony-resistance (12, 13)
The other parental drug is amphotericin B deoxycholate which is a polyene antibiotic used
in systemic fungal infections, and typically, the second line of treatment for leishmaniasis (5).
Amphotericin B deoxycholate is mostly used for the treatment of VL, with high efficacy rates
close to 100% (14). Based on safety, tolerance, and remarkably high-level efficacy in VL, the use
of IV liposomal amphotericin B has been reasonably extrapolated to CL and ML (15). Besides its
high efficacy, adverse effects such as hepatotoxicity, hypokalemia, nephrotoxicity, myocarditis,
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or even death have been previously documented, therefore, hospitalization may be necessary for
monitoring of patients (14). Furthermore, lipid formulations such as AmBisome, at 21 mg/kg IV
per day dose are also used for treatment of CL. Nonetheless, liposomal amphotericin B is
extremely expensive due to the cost of the drug itself ($280 per 50 mg vial) in addition to the cost
of IV administration. Even though Gilead Sciences and the World Health Organization (WHO)
agreed to lower the price in endemic regions to $20 per 50 mg vial of AmBisome in 2007, a total
dose of 20 mg/kg is needed ($480 for a 60 kg person) (14).
Other options for treatment are the oral therapies with miltefosine and the azoles,
ketoconazole and fluconazole. Miltefosine (hexadecyl phosphocholine) was first introduced as an
anticancer drug, however, in the 1980’s miltefosine exhibited anti-leishmanicidal activity (16).
Currently, it is the only effective oral treatment against CL and MCL (17). More importantly, in
2014, the Food and Drug Administration (FDA) approved miltefosine or IMPAVIDO (Paladin
Therapeutics, Canada) for the treatment of CL and MCL in the United States (18). According to
the FDA, the treatment is available as 50 mg-capsules and administered at 2.5 mg/kg/day (up to
150 mg/day) in two or three divided doses for 28 days (19)., IMPAVIDO presents several
limitations for its use, teratogenicity being the most adverse limitation but it also regularly
produces headaches, nausea, vomiting, and/or diarrhea in a significant percentage of patients,
typically during the first week of treatment(11). Additionally, miltefosine has a long half- life (150
hours), which may facilitate the emergence of drug resistance (5). Another limitation is that the
efficacy of IMPAVIDO differs between Leishmania species, for instance, CL caused by L.
panamensis showed 70 to 90% cure rate, on the other hand, CL caused by L. mexicana less than
60% (5). Another, but not to a larger extent, oral option are the azoles ketoconazole and
fluconazole. There is some evidence to support the use of high-dose fluconazole for the treatment
of old-world CL caused by L. major (20) and new-world CL caused by L. braziliensis (21) as well
as the high-dose use of ketoconazole for L. panamensis and L. mexicana infection (22). However,
as with the other treatment option, azoles present many adverse effects that include gastrointestinal
symptoms and hepatotoxicity and with such high doses, serum chemistries need to be monitored
6

weekly. Even tough, an oral treatment is ideal for diseases such as leishmaniasis, the treatments
mentioned here are far from ideal because all the adverse characteristics each agent has. Therefore,
it is important to emphasize the need of novel possibilities for the treatment for leishmaniasis.
1.1.2

Leishmania sp. surface glycoconjugates
The different stages of the Leishmania parasite (promastigote, metacyclic promastigote and

amastigote) are characterized by morphological and structural changes correlated with molecular
modulations of the glycocalyx, a dense glycoprotein and glycolipid cover that surround its cell
membrane. These glycosylated elements are generally anchored to the membrane by
phosphatidylinositol (PI) (Fig 1.5). These complex glycoconjugates are thought to be key
determinants of parasite virulence in both the insect vector and mammalian host (23). The
glycolipids include small glycoinositolphospholipids (GIPL) with less than eight glycosidic units,
lipophosphoglycan (LPG) which is a polymer of phosphorylated saccharide units, and the
glycoproteins include proteophosphoglycans (PPGs), proteins highly glycosylated by the same
repetitive patterns as LPG and glycosylphosphatidylinositol anchored proteins (GPI-AP) (24). It
is worth to mention that the composition and size of this coat will vary not only with species, but
also with the stage of development of the parasite as it reaches 6 nm in procyclic promastigotes
and changes to up to 20-40 nm as it developed into metacyclic in the insect and its dominated by
LPG, GPI-AP and GIPL (24, 25). In contrast, in amastigotes, it is extremely reduced and its mainly
coated with GIPL and host-derived glycosphingolipids (GSL) (26) (Fig 1.6).
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Figure 1.5 Main glycoconjugates at the surface of leishmanial promastigote cells
Abbreviations: LPG: lipophosphoglycan; fPPG: filamentous proteophosphoglycans; mPPG:
membrane
proteophosphoglycans;
sAP:
secreted
acid
phosphatases;
GPI:
glycosylphosphatidylinositol; GIPL: glycoinositol phospholipids. Adapted from Cabezas et al.
2015.
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Figure 1.6 Glycoconjugate evolution in the three stages of Leishmania parasites.Adapted from
Cabezas et al. 2015.

LPG is the major glycoconjugate in promastigotes, covering its surface as well as its
flagellum but it is also present at very low levels in amastigotes (27). The backbone structure of
LPG is highly conserved in all Leishmania sp. and it consist of a long phosphoglycan made up of
a 20-40 repeating Galβ1-4-Manα1-PO4 that is anchored via a unique hexaglycosyl GPI anchor
(28). While the backbone and anchor are conserved among all Leishmania spp., differences in the
lateral substitution and the cap are species/stage-specific and found to be adapted to sandfly species
(29, 30)The LPG firstly ensures attachment of the parasite, probably through interactions with
specific lectins, to the digestive tract of the insect so it is not dragged along with the blood meal
(31). Between procyclic promastigote and metacyclic promastigote, the number of repetitive units
grows from 15 to about 30, thus increasing the thickness of the glycocalyx (32). It is likely that
these conformational changes induce the variation of host to guest interactions so metacyclic
promastigotes migrate to the anterior midgut and later to the proboscis (29). Secondly, a dramatic
increase of superficial LPG, which was also shown to be complement-resistant from procyclic to
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metacyclic promastigote contributes to inoculation to the mammalian host and prevent phagosome
maturation giving enough time for differentiation to amastigote (23). Another glycolipid class
present are the GIPLs. Though of low molecular weight, GIPLs are present in ten times more
copies than LPG, are present on all parasite’s stages and the number of copies remains constant
during the life cycle (24). Their glycosylphosphatidylinositol anchor structure, found in all
eukaryotes, is based on the trisaccharide Manα1,4GlcNα1,6-myo-Ino linked to a glycerolipid part
that ensures anchoring into the cell membrane(25). There are three main families depending on
whether the oligosaccharide structure is close to that of the GPI anchor proteins Manα1,6
Manα1,4GlcNα1,6-PI (type-1 GIPL, high mannose) or to the core of the LPG
Manα1,3Manα1,4GlcNα1,6-PI (type-2 GIPL enriched in galactose in both pyranose and furanose
forms)

or

whether

the

glycoside

is

a

hybrid

of

the

two

last

ones

Manα1,6(Manα1,3)Manα1,4GlcNα1,6-PI (23). GIPLs may have variable influence on the
survival of the parasite, depending on the species and/or the stage of the parasite since
contradictory results have been obtained in different Leishmania sp. regarding survival, growth
and virulence (23-25).
The other components of the Leishmania glycocalyx are the glycoproteins PPG and GPIAP. PPGs are highly glycosylated, but unlike typical forms of glycosylations (N-and O-glycans),
they are phosphoglycosylated and present Manα1-PO4 connected to serine or threonine residues
(24). The PPGs may exist in several forms: membrane bound (mPPG) which is also considered a
GPI-AP, secreted (sPPG) or filamentous (fPPG) (33). fPPG plays a vital role as it is one of the
components of viscous net around the parasite which ensures protection of the parasites within the
insect vector (34). sPPG plays a role in signaling processes involved in the pro-inflammatory
response due to the high mannose, thus activating complement system via mannose-binding
receptor (35). The function of mPPG is not yet well understood but its long structure and abundant
presence allow speculation that mPPG makes the parasite highly accessible for ligand binding
(33). Thus, mPPG could be a potential ligand for macrophage and insect vector midgut receptors.
Furthermore, the surface glycocalyx of Leishmania contains at least three GPI-AP that have
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discovered so far, GP63, also called leishmanolysin, PSP (Promastigote Surface Protein) or MSP
(Major Surface Protein), and GP46, or PSA2 (Promastigote Surface Antigen) and the already
mentioned mPPG (24). All three glycoproteins are mostly downregulated as promastigotes
differentiate to amastigotes, suggesting that they are primary required for life in insect vector and
during infection (36, 37). GP63 is a 58-65 kDa zinc metalloprotease more present on the surface
of promastigotes than on amastigote for which its losses the GPI anchor and appears mainly in the
flagellum pocket(38). High mannose-type glycans complete the structure of GP63 (39). The role
GP63 is still unclear. Nevertheless, GP63 is able to; disturb the extracellular matrix surrounding
the parasite, thus facilitating movement in tissues, confers protection against complementmediated lysis, and improves internalization into macrophages (35, 40). As for GP46, it is involved
in the attachment of the parasite onto macrophages and in cell invasion(35)
1.1.3

Biomarkers for the discriminatory and follow-up diagnosis for the different clinical
manifestations of leishmaniasis
Despite several studies on leishmanial glycoconjugates, there are still many questions

unanswered. There is a potential for the development of treatments, diagnosis strategies or
vaccines based on the already mentioned glycoconjugates above, but they are conditioned by the
variability of glycan structures between species (side chains and epitopes) and a lack of
standardization of immunoassays. Having oligosaccharide fragments and epitopes characterized
would provide means necessary for the development of more reliable discriminatory and followup diagnostic methods.
The key features of any detection assay for any infective agent including Leishmania are:
i) sensitivity, ii) specificity, iii) speed, iv) accuracy, v) accessibility, vi) ease of use, and vii)
applicability in the field. In the case of leishmaniasis, additional factors should be considered, such
as discriminatory power, ability to detect and quantify Leishmania spp. in biological samples and
cost-effective since many leishmaniasis cases occur in developing countries (41). These factors
11

make parasitological methods such as microscopic examination, isolation and parasite culturing,
obsolete. Even though these methods have low cost, they are time consuming and possess low
sensitivity and specificity(2). The same happen for methods such as quantitative polymerase chain
reaction (qPCR), gene sequencing and matrix-assisted laser desorption ionization time-of-flight
(MALDI-TOF) that even though they have a great sensitivity, specificity and great discriminatory
power, they are expensive techniques, and required extensive training (2). These factors leave two
of the most widely used diagnosis tools, conventional PRC and enzyme-linked immunosorbent
assay (ELISA). However, they can only detect a single or a few Leishmania sp. and therefore are
not suitable for areas with several sympatric species (42). Furthermore, follow-up methods for
leishmaniasis treatment and clinical trials also present several disadvantages. Classical clinical
features used to evaluate individual treatment responses of patients with VL include the
normalization of spleen/ liver size, and the normalization of blood cell counts as an indicator of
recovering bone marrow (43). For CL, the sizes of the inner and outer borders of cutaneous lesions
are used as determinants of parasite biomass (44). These individual clinical features are, however,
rarely used in the quantitative comparison of antileishmanial therapies in the context of a clinical
trial (42). Within such trials, the current standard confirmation of initial cure for VL is a
Leishmania-negative spleen or bone marrow aspirate confirmed by microscopy, a very invasive
semiquantitative technique which cannot be regularly repeated (45, 46). For CL, the confirmation
of initial cure is much less clear: most clinical trials have defined “cure” as the absence of all
inflammatory signs (skin edema and/or hardening) and complete scarring of ulcerative lesions at
the 3-month follow-up (44, 47). For both VL and CL, confirmation of a final cure as a primary
endpoint is even more complicated by the long time periods between initial cure and reactivation
of parasites, requiring long follow-up periods (up to 6 or 12 months) to establish final cure (48).
Parasite reactivation is a rare and slow-developing event which is difficult to predict, mainly
because little is known about the causes or risk factors (42). Thus, there is an urgent need for new
diagnosis methods that are discriminatory and that can be used for follow-up of leishmaniasis
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chemotherapy that are faster, more reliable and less invasive than conventional clinical
evaluations.
To this end, the use of biomarkers could be the answer. One of these biomarkers could be
terminal nonreducing epitopes that are highly immunogenic to humans, due to the inactivation of
the α1,3-galactosyltransferase (a1,3-GalT) gene millions of years ago, in our ancestral primates
(49). The α-gal-like epitopes are carbohydrate epitopes that may have a structure resembling αgal epitopes, with terminal α-galactosyl linked to the penultimate carbohydrates in an α1-2, α1-3,
or α1-6 linkage, and which can bind some of the anti-Gal antibody in human serum (50). There is
evidence that infected patients with various Leishmania strains had elicited anti-Gal production in
patients(50). This, in turn, motivated researchers to determine whether glycoconjugates on the cell
membrane have α-gal-like epitopes. Initial studies evaluated the binding of purified human antiGal and of monoclonal anti-Gal antibody Gal-13 (51) to L. mexicana promastigotes by ELISA.
Both antibodies displayed specific binding to the parasite as well as to lipid fractions extracted
from the parasites (52). In other Leishmania spp. such as L. mexicana and L. braziliensis, analysis
of carbohydrate epitopes extracted demonstrated the presence of large quantities of an α-gal-like
epitopes with the structure Galα1-3Man (53). Similarly, analysis of the glycolipids in Leishmania
demonstrated that some of the glycoinositol phospholipids from L. major, L. mexicana, and L.
braziliensis have Galα1-3Gal, Galα1-6Gal, and Galα1-3Man epitopes (54-57). Therefore, purified
glycoconjugates with terminal α-gal could be used as biomarkers for discrimination and followup diagnosis. This is because, unlike protein antibodies, carbohydrate specific antibodies disappear
from circulation soon after elimination of the parasite from the infected host , indicating that αGal glycotopes are highly specific for accurate diagnosis and early assessment using ELISA
techniques (58). Furthermore, another alternative would be the use of synthetic neoglycoproteins
(NGPs) consisting of bovine serum albumin (BSA) decorated with many α-Gal-containing
glycotopes which are based on glycans found in Leishmania spp. as it has been proposed as
biomarkers for Chagas disease and tried as prophylactic vaccine for CL (59-62).
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1.2 CHAGAS DISEASE AND TRYPANOSOMA CRUZI
Chagas disease, also referred as American Trypanosomiasis, is caused by the protozoan
parasite Trypanosoma cruzi. It currently affects 6-7 million people worldwide (63). First described
by Dr. Carlos Chagas in Brazil 1909 and the disease grew recognition as an important infection in
Central and South America in the 1960s (64). It has remained endemic from Mexico to Argentina
with estimation of more than 10,000 death per year and in recent years, there is an estimation that
300,000 individuals currently reside within the United States (65, 66). Because of the potentially
long interval between infection and presentation with symptoms, patients acquiring the infection
in endemic regions can emigrate and later present for care in communities around the world (66,
67) (Fig 1.7). T. cruzi is transmitted by several routes, including insect-vector transmission blood
transfusion, transplantation, consumption of contaminated foods and fluids, congenitally (68).
Once infected, the disease in humans can unfold in two main phases. An acute illness sometimes
occurs in the weeks or months after infection producing fevers, myalgias, headache, or nonspecific
GI symptoms and it common for the disease to go unnoticed with minimal symptoms (69). Chagas
can progress to a chronic form of the disease. This occurs in approximately one third of patients
and primarily affects the heart causing cardiomyopathy, and the GI system causing syndromes
such megacolon and megaesophagus (69, 70).
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Figure 1.7 Global distribution of cases of Chagas disease, based on official estimates, 2006–
2010. Adapted from World Health Organization, 2010

T. cruzi is transmitted by triatomines (commonly known as kissing bugs), which feed on
mammalian blood. Triatomine insect vectors ingest during a blood meal acquisition from a
vertebrate host. After ingestion, bloodstream trypomastigotes will transform into epimastigotes in
the insect midgut. T. cruzi epimastigotes will then multiply and migrate to the hindgut where they
will differentiate into infective and non-replicative metacyclic trypomastigotes. These forms are
eliminated with the triatomine feces and urine after a successful blood feeding. Metacyclic
trypomastigotes will infect a host when the feces near the wound or bite site are introducing shortly
defecation. They can infect any nucleated cell. Inside the host cells, the parasite will differentiate
into replicative noninfective intracellular amastigotes which then will multiply by binary fission
in the cytoplasm of host cells. At high intracellular parasite densities, amastigotes will differentiate
into mammalian tissue cell-derived trypomastigotes that will burst out of the host cell, allowing
the parasite to re-infect neighboring cells or go back into the host bloodstream. Eventually, this
cycle is repeated when another triatomine takes a blood meal from an infected individual (Fig. 1.8)
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Figure 1.8 Life cycle of Trypanosoma cruzi.
Adapted from the Center of Disease Control (CDC)
1.2.1 Triatomine, vector of Chagas disease
Transmission of T. cruzi occurs mostly via the hematophagous insect vector triatomine
Triatominae insects (Hemiptera: Reduviidae) (71) are a diverse subfamily of ectoparasites mainly
distributed across Americas (72). The Triatominae are grouped in 17 genera and organized into 5
tribes: Aberproseniini, Bolboderini, Cavernicolini, Rhodiniini, and Triatomini (73). Currently, 151
Triatominae species have been described, 141 in the Americas (73). Moreover, six species
belonging to the genus Linshcosteus occur in India, and species belonging to Triatoma have been
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also identified in Africa, the Middle East, South-East Asia and in the Western Pacific (74) (Fig
1.9). They are typically found in a wide range of sylvatic environments frequently associated to
several wild vertebrate hosts, possibly in their nests and burrows. Triatomine bugs in the Americas
inhabit both forests and drier areas. Many species feed on wild animals, such as armadillos,
iguanas, opossums, rats, marsupials, ground squirrels, skunks, bats, as well as birds as well as
peridomestic animals such as donkeys, cattle, goats, horses, pigs, cats, dogs, chickens, and humans.
Sylvatic Triatoma species shelter in the burrows or nests of wild animals, as well as fallen logs,
tree-holes and caves while peridomestic Triatoma species often live-in man-made structures
including houses, especially primitive ones made of wood, mud and thatch. Contact with humans
occurs when men enter in areas occupied by the insect or when they reach urban areas by flying
and colonize human dwellings (75). All species are considered able to transmit T. cruzi (74).
However, those belonging to the genera Triatoma, Rhodnius and Panstrongylus have greatest
epidemiological importance in Latin America as they have adapted to colonize peridomestic and
domestic environments, coming into close contact with peridomestic animals and humans (76).
Domiciliation have occurred through the loss of habitat due to environment destruction, such as
deforestation, burnings and construction of human buildings and housing (77) or through the loss
of primary hosts, which can triggers a switch to accessible humans (78).
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Figure 1.9 Worldwide Triatominae distribution.
Triatominae species are present mainly in Americas (green), in which countries one or more genera
can be found. Outside the American continent (blue), the only genus reported is Triatoma, except
in India (orange), where Triatoma and Linshcosteus are reported. Adapted from Barreto Viera et
al. 2018

Triatomines are obligate hematophagous insects, exhibiting behavioral, morphological and
molecular adaptations to feed on a variety of vertebrate blood throughout their life cycle (75) in
which they undergo five nymphal stages before reaching adulthood (79). The life cycle from egg
to adult can take 3–10 months, larger triatomine species the life cycle may last 1–2 years (80).
Nymphs and adults of both sexes feed at night on their hosts and feeding often lasts 10–25 minutes
(75). Young nymphs can ingest 6–12 times their own weight of blood while successive instars take
relatively less blood, so that the fifth and last nymphal stage takes about 3–5 times its own weight
of blood, while adults ingest 2–4 times their weight of blood (81). Adults of some species ingest
300–400 mg of blood at each meal and feed every 4–9 days, In the absence of hosts, older nymphs
and adults can survive 4–6 months of starvation (81). Adult females lay 1–2 eggs a day. The total
number of eggs laid varies from 50 to 1000, depending on the species, their longevity and the
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number of blood-meals they take, but it is estimated to 200–300 eggs (81). In the absence of hosts,
older nymphs and adults can survive 4–6 months of starvation(82). Therefore, their dietary
behavior and life cycle ensures the scenario to act as potential vectors of T. cruzi to humans at any
developmental stage.
1.2.2 Vector control for Chagas disease
There are several strategies for the prevention and control of Chagas disease. Currently,
only two drugs are available for treatment: benznidazole and nifurtimox. Although these
chemotreatments are very effective in the acute phase, they become less effective as the disease
progress into the chronic phase. Moreover, these drugs are highly toxic resulting in treatment
interruption in 20- 30% of patients. In the case of a prophylactic or therapeutic vaccine, there has
been many improvements in the vaccine development, but no vaccine has been made available.
One more strategy for the prevention and control of Chagas disease is through vector
control. Control of Chagas disease is mainly by spraying the interior surfaces of walls and
roofs/ceilings of houses, outhouses, chicken sheds and goat pens with residual insecticides.
Although fenitrothion (organophosphate) is sometimes used, pyrethroids are the most sprayed
insecticides, particularly deltamethrin, cyfluthrin and lambda-cyhalothrin. Bug populations can be
reduced by making houses unattractive as resting sites: for example, by plastering walls to cover
up cracks in which the bugs might hide, and by replacing dilapidated mud and thatched houses
with those built of bricks or cement blocks and having corrugated metal roofs. However, for these
strategies to work, active surveillance needs to be in place. Only 10-20% of Chagas disease
published data deals with triatomine ecology control and surveillance. This indicates there is a lack
of surveillance research towards Chagas disease and triatomines. One place that could be
beneficiated for active surveillance would El Paso County in Texas. El Paso shares the same
ecoregion as places in Arizona where many triatomines have been located and is closed to other
counties in Texas where large triatome populations have been reported (83). Active triatomine
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surveillance in places such El Paso will give evidence for the presence of triatomines in the area.
Monitoring and evaluation of triatomines in cities such El Paso will allow to assess entomological
risk, human health risk and will allow the creation of vector control programs, that in turn, will
help in the prevention of Chagas disease in cities where the disease is beginning to emerge.
1.3 CENTRAL OBJECTIVE & SPECIFIC AIMS
Central objective: The main goal of this project is to evaluate different strategies for the treatment,
diagnosis and prevention (vaccine prevention and vector control) of Leishmaniasis and Chagas
disease. In this study we used several approaches and worked focusing in three hypotheses.

Hypothesis 1: Based on evidence on the literature on methionine aminopeptidase 1 inhibitors and
thiophene derivatives behavior and previous results in our laboratory, we hypothesized that these
compounds would have a potent leishmanicidal effect in vitro and in vivo model for CL and with
no toxic effects. We hypothesized that MetAP1 inhibitors will act on target inhibiting MetAP1
enzyme and that thiophene derivatives will induce an apoptotic-like mechanism. Thus, both
compounds will subsequently kill the parasite.
Specific aim 1: Evaluate novel compounds with anti-leishmanial properties and no cytotoxic
effects towards mammalian cells in-vitro and in an in-vivo animal model for cutaneous
leishmaniasis.
Hypothesis 2: We hypothesized that purified GPI-AP with terminal α-gal could be used as
biomarkers for discrimination and follow-up diagnosis of leishmaniasis. This is because, unlike
protein antibodies, carbohydrate specific antibodies disappear from circulation soon after
elimination of the parasite from the infected host, indicating that α-Gal glycoepitopes are highly
specific for accurate diagnosis and early assessment using ELISA techniques as it has been shown
for Chagas disease
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Specific aim 2: Characterize and evaluate ⍺-gal containing glycosylphosphatidylinositol
anchored-proteins (GPI-AP) from Leishmania sp. that can be used as biomarker candidates.

Hypothesis 3: While there is increasing evidence of Chagas disease in Texas, epidemiologic
assessment studies on this disease have not been conducted in southwest Texas, which includes El
Paso, and surrounding areas. We hypothesized that infection of T. cruzi in El Paso has been
underestimated. Therefore, we propose a comprehensive surveillance in the region.
Specific aim 3: Survey El Paso and surrounding areas for Chagas disease: triatomines, domestic
and wild animals.

21

Chapter 2: Thiophene derivatives and methionine aminopeptidase 1 (MetAp1) inhibitors as
chemotherapies for cutaneous leishmaniasis
2.1 INTRODUCTION
Leishmaniasis is a devastating neglected tropical disease (NTD) (1) caused by the
protozoan parasite of the genus Leishmania. The parasite is transmitted from animals to humans
through the bite of infected females Lutzomyia or Phlebotomus sand flies (84). Over 20 species
and subspecies of Leishmania infect humans, causing three major clinical forms of the disease:
cutaneous (CL), visceral, and mucocutaneous leishmaniasis (85). The prevalence of CL, the most
common form of leishmaniasis, is estimated between 0.7 and 1.3 million new annually cases
worldwide (86), and it is commonly caused by Leishmania major (L. major) or L. mexicana. CL
presents as singular ulcerative or nodular lesions at the bite site that may resolve into scar tissue,
often leading to scarring and social stigma (87). The disease is present in both, the Old World in
regions of the Middle East, Africa, Central Western and Easter Europe; and the New World in
regions of Central and South America, and more recently in North America (87). Nonetheless,
with increases in travel, military activities, and migration, the disease presents a risk for
populations that were previously unaffected, including in the United States, where CL is nowadays
considered an emerging concern (88-91).
2.1.1 Current treatments for Leishmaniasis
Currently, there is no preventative or therapeutic human vaccine available against any
clinical manifestation of the disease, and available treatments such as pentavalent antimonials
(Glucantime and Pentostam), liposomal amphotericin B (AmBisome®), and miltefosine
(IMPAVIDO®) present several disadvantages (92). Pentavalent antimonial treatments are the first
line of action; however, systemic therapy is required for more than 20 days, with toxic side effects
including cardiotoxicity and hepatotoxicity (93, 94). Amphotericin B is highly active, but has
extensive toxicity complications (nausea, vomiting, rigors, fever, hypertension or hypotension, and
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hypoxia) that usually lead to treatment interruption; besides, its administration requires
hospitalization, and its high cost limits its use in developed countries (87, 95). Miltefosine is the
only oral agent against leishmaniasis, however, it presents several limitations such as embryo-fetal
toxicity, fetal death, and its long half-life (150 h) may facilitate the emergence of drug resistance
(5, 96). Thus, these facts clearly emphasize the urgent priority for the development of novel
chemotherapies against leishmaniasis.
2.1.2 Thiophene derivatives
Considering the current interest in the search of antileishmanial agents, it has been
previously reported for the first time that aryl alkylamine type-compounds exhibit anti-Leishmania
activity with no toxicity to mammalian cells (97, 98). Toward our medicinal chemistry effort in
developing novel compounds with anti-parasitic activity and drug like properties (e.g., improved
solubility, potency, stability and less or low toxicity), we assessed the antileishmanial activity of a
series of novel compounds based on the thiophene scaffold with pharmaceutical properties: low
toxicity, improved potency and solubility (98). In this context, in the present study, we evaluated
nine synthetic thiophene molecules derivatives against L. major in vitro.
We set a goal to design and synthesize a scaffold with antileishmanial activity in a one- or
two-step synthesis using simple and efficient chemical transformations with high yield, high atom
economy and inexpensive starting material. In this study, we focused on the creation of substituted
thiophenes which are considered among the privileged structures in drug discovery (99).
Substituted thiophenes are known with their various biological activities such as anti-microbial,
anti-cancer, and anti-inflammatory properties (99). Therefore, the development of novel thiophene
compounds with activity against Leishmania is crucial and urgent, as they may also complement
current drugs and overcome drug resistance.
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2.1.3 MetAP1 inhibitors
Essential enzymes like methionine aminopeptidase (MetAP) have been suggested as
promising targets for the development of novel antiparasitic agents. Methionine aminopeptidases
are classified into two different types, MetAP1 and MetAP2. The latter contains a 60-amino-acid
insertion that distinguishes it from MetAP1 (100, 101). MetAP1 is a dinuclear metalloprotease that
catalyzes the removal of N-terminal methionine residues from peptides and proteins (101, 102).
MetAP1 proteins bind to metal ions like cobalt or zinc for their activity (103), and disruption of
MetAP1 impairs proper protein folding, posttranslational modifications, biologic maturation, and
translocation of some newly synthesized peptides and proteins within the cell (104). The
functionality and importance of MetAP1 has been shown in several organisms, including
Escherichia coli, Salmonella enterica serovar Typhimurium, and Mycobacterium tuberculosis,
where the knockdown of the MetAP1 gene leads to lethal effects or reduced viability (105-107).
In Saccharomyces cerevisiae, the knockdown of MetAP1 leads to slow growth, while the
knockdown of MetAP1 and MetAP2 leads to nonviable yeast strains (108). Furthermore, studies
have been made of MetAP1b in the protozoan Plasmodium falciparum (PfMetAP1b), one of four
types of MetAP found in P. falciparum. The observation of antiproliferation effects on several P.
falciparum strains by highly selective inhibitors of PfMetAP1b has led to the discovery of selective
MetAP inhibitors (100). Moreover, MetAP inhibitors have shown promising results against
tuberculosis, fungal infections, rheumatic disease, various forms of cancer, malaria, leishmaniasis,
and other diseases (100, 107-115). Unlike the protozoan P. falciparum, only one methionine
aminopeptidase has been discovered in L. major (MetAP1Lm), which has a 50% sequence similarity
with human MetAP1 (MetAP1 of Homo sapiens [HsMetAP1]) and less than 14% similarity to
human MetAP2 (HsMetAP2). Another report highlighted the potential role of type 2 MetAP in
Leishmania donovani (116), and a recent study reported the expression, purification, and
characterization of MetAP1 in L. donovani, giving more evidence of MetAP1 as a drug target for
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Leishmania spp. (117). Therefore, we selected methionine aminopeptidase 1 (MetAP1) as a
prospective chemotherapeutic target.
Using an integrated whole-cell-based screening and chemogenetic approach, we
systematically identified and characterized three novel MetAP1Lm inhibitors. Previously, a highthroughput screen consisting of a library of 175,000 structurally diverse small molecules was
conducted by Olaleye et al. (107). Their study successfully identified lead MetAP1 inhibitors
against M. tuberculosis (107). As part of the drive to find new antileishmanial treatments, we
screened and characterized the antiparasitic activity of these novel MetAP1 inhibitors against CL
infection caused by L. major in vitro and in an in vivo model. MetAP1Lm inhibitors OJT006,
OJT007, and OJT008 showed potent leishmanicidal activity and remarkable selectivity indexes in
vitro. More importantly, OJT008 significantly reduced the parasitic load with no evident toxicity
in a preclinical in vivo model. These findings suggest MetAP1Lm as a potential therapeutic target
for the development of efficient and nontoxic drugs against CL. MetAP1 can serve as a potential
target for the development of novel anti-infective agents to combat the emergence of drug-resistant
pathogens.
2.2 MATERIALS AND METHODS
2.2.1 Compounds
Thiophene derivatives (5A-I) were synthesized in Dr. Rachid Skouta’s lab at University of
Texas at El Paso (UTEP) as follow: General Synthetic Procedure 1 (Synthesis of the Ethyl 5,5,7,7tetramethyl-2-(4-(trifluoromethyl)

benzamido)-4,5,6,7-tetrahydrothieno

[2,3-c]pyridine-3-

carboxylate (5A)). Briefly, the 2,2,6,6-tetramethylpiperidine ketone (1, 1 equivalent) was mixed
with 2-cyanoacetate esters (2, 1 equivalent) and elemental sulfur (1 equivalent) in the presence of
diethylamine (3 equivalents) in ethanol (ETOH) at 60 ◦C for 17 h. The crude was precipitated by
adding water and filtered to provide the desired known 2-aminothiophene intermediate (3)(97).
The latter was reacted with 4-trifluomethy benzoyl chloride in the presence of
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diisopropylethylamine in dry dichloromethane at 0 ◦C for 1 h and then at room temperature for 4
h. The solvent was evaporated then the crude mixture was purified by flash-column
chromatography on silica gel, using a mixture of solvent of dichloromethane: methanol (DCM:
MeOH) at ratios from 100:1 to 50:1, to provide the desired ethyl 5,5,7,7-tetramethyl-2-(4(trifluoromethyl)benzamido)-4,5,6,7-tetrahydrothieno [2,3-c]pyridine-3-carboxylate (5A) as a
light brown solid. The purity of 5A was confirmed by 1H-NMR, 13C-NMR, LC/MS and melting
point.

General

Synthetic

Procedure

2

(Synthesis

of

5,5,7,7-tetramethyl-2-(2-

(trifluoromethyl)benzamido)-4,5,6,7-tetrahydrothieno [2,3-c]pyridine-3- carboxylic acid (5G)).
To ethyl 5,5,7,7-tetramethyl-2-(2-(trifluoromethyl)benzamido)-4,5,6,7-tetrahydrothieno [2,3-c]
pyridine-3-carboxylate compound (5B; 1 equiv.) in 1 mL of tetrahydrofuran (THF), was added 5
equiv. of sodium hydroxide (NaOH) in water (1 mL). The mixture was stirred at room temperature
during 17 h. The THF solvent was evaporated then mixture was acidified with HCl 1M to pH = 4.
The protonated acid compound was extracted with ethylacetate (EtOAc) (3×; 50 mL) then dried
under magnesium sulfate (MgSO4), and the solvent was evaporated to provide the desired 5,5,7,7tetramethyl-2-(2-(trifluoromethyl)benzamido)-4,5,6,7-tetrahydrothieno

[2,3-c]pyridine-3-

carboxylic acid (5G), (Figure 2). The purity of 5G analog was confirmed by 1H-NMR, 13C-NMR,
and LC/MS. Following the general synthetic procedure 1, and in the presence of various
substituted benzoyl chlorides, analogs 5B–5E, and 5H–5I were created.
Methionine aminopeptidase 1 inhibitors (OJT 001-008) were synthesized in Dr. Olaleye’s
lab at Texas Southern University. Previously, a screening of 175,000 diverse small molecules
conducted by Olaleye et al. (107) led to the discovery of eight potent MetAP1 inhibitors (OJT001
to OJT008). The eight MetAP 1 inhibitors tested belong to four structurally diverse classes of
small-molecule compounds affiliated with four structurally distinct chemical classes. Compounds
OJT001 to OJT005 are five analogues belonging to the 8-hydroxyquinoline chemical class and are
structurally related analogues with the same pharmacophore (111), while compounds OJT006,
OJT007, and OJT008 are all structurally different, with diverse pharmacophore classes. OJT006

26

is a pyridoxal isonicotinoyl compound, OJT007 has the hydrazine-1-ylidene-containing
pharmacophore, and OJT008 has the pyrimidin-4- amine pharmacore.
2.2.2 Animals and ethics statement
BALB/c mice aged 6 to 8 weeks were bred and maintained in a pathogen-free animal
biosafety level 2 (ABSL-2) facility at the Laboratory Animal Resources Center (LARC) at The
University of Texas at El Paso (UTEP). All animal studies and procedures were performed to
minimize the distress and pain for the animals in accordance with the NIH guidance and animal
protocol A-201107-1, approved by UTEP’s Institutional Animal Care and Use Committee
(IACUC).
2.2.3 Cell Maintenance
L. major-luc Friedlin clone V1 promastigotes expressing firefly luciferase Lmj-FV1-LUCTK (L. major strain Friedlin [MHOM/JL/80/Friedlin]) were cultured at 28°C in M199 medium
(Sigma-Aldrich) supplemented with hemin, 10% heat-inactivated fetal bovine serum (iFBS;
Gibco), 1% 10,000 U/ml penicillin, 10 mg/ml streptomycin (Gibco) and treated with 50 ng/ml of
streptothricin neosulfate (GoldBio) for maintenance of the luciferase (luc) gene. Starch-induced
intraperitoneal BALB/c mouse macrophages (IPf) were obtained as described previously and were
cultured in Dulbecco’s modified Eagle’s medium (DMEM; Thermo Fisher Scientific)
supplemented with 10% iFBS (Gibco), 1% 10,000 U/ml penicillin, and 10 mg/ml streptomycin
(Gibco).
2.2.4 Luciferase viability assay
MetAP1 inhibitors (OJT001-008) and thiophene derivatives (5A-I) were screened against
L. major-luc promastigotes. First, parasites at 1x106/ml were added to 96-well, white, flat-bottom
Nunc plates (Thermo Fisher Scientific) together with the inhibitors or derivatives in a final
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concentration range from 0.005 µM to 100 µM, in triplicates, followed by 72 h of incubation at
28°C. Amphotericin B (Sigma-Aldrich) was used at 5 µM as the drug of reference. The efficacies
of the compounds were assessed by monitoring parasite survival by luciferase activity. The
substrate 5’-fluoroluciferin (ONE-Glo luciferase assay system; Promega) was added according to
the manufacturer’s protocol, and the signal read in a luminometer (Luminoskan; Thermo Fisher
Scientific). The luminescence intensity was a direct measure of the parasite survival, and 50%
effective concentration (EC50) was determined for each drug.
2.2.5 Mammalian cell cytotoxicity
Inhibitors OJT 006, OJT 007, OJT 008 and derivatives 5D or 5E at different concentrations
were incubated with 1 × 105 cells/mL IPΦ for 48 h at 37 ◦C, 5% CO2. After the incubation period,
a dilution of 20:1000 in PBS from a stock at 1 mg/mL of Propidium Iodide (PI) and Hoechst 33342
(Thermo Scientific) were added for survival discrimination as previously described (118).
Analysis was performed by High-Content Imaging Assay (HCIA) using an IN Cell 2000 Analyzer
Bioimaging System (GE Healthcare). The 50% cytotoxic concentration (CC50) and selective
index (S.I.) was determined.
2.2.6 In vitro proliferation evaluation of by high-content imaging assay
BALB/c IPΦ were acquired and seeded at a density of 1 × 105 cells/mL for 2 h at 37 ◦C,
5% CO2. After adherence, IPΦ were infected with 1 × 106/mL metacyclic promastigotes of L.
major-luc, at a ratio of 10:1 parasite per macrophage. Subsequently, infected IPΦ were incubated
with inhibitors OJT 006, OJT 007, OJT 008 and derivatives 5D or 5E at increasing concentrations
(0.625 to 20 μM) for 48 h treatment. Afterwards, cells were fixed with 4% paraformaldehyde, and
stained with (1.25:100) Alexa Fluor 488 Phalloidin (Thermo Fisher Scientific) and (1:1000) DAPI
(Sigma Aldrich). Then, the numbers of infected cells and amastigotes were determined by HCIA
using an IN Cell 2000 Analyzer Bioimaging System (GE Healthcare). Parameters were set for the
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excitation and emission spectra of Alexa Fluor 488 Phalloidin and DAPI, and a constraint of 3, 5
or more parasites per macrophage was set as previously reported (119). To determine the quality
of the assay, 10 replicates of each control, 1% DMSO and amphotericin B, were carried out to
calculate the Z factor.
2.2.7 Homologous overexpression of MetAP1Lm
The MetAP1Lm gene was amplified from L. major genomic DNA using the oligonucleotides
MetAP1Lm-XbaI

sense

(5’-TCTAGAGGATCCATGCCCTGCGAAGGCTGCGGC-3’)

and

MetAP1Lm-XbaI antisense (5’-TCTAGAGAATTCTCAGATTTTGATTTCGCTGGGGTCTTCG
G-3’). PCR was performed using PCR master mix (Promega), 420 ng of L. major genomic DNA,
and MetAP1Lm sense and antisense primers under conditions of denaturation of 5 min at 95°C,
followed by 40 cycles of 60 s at 95°C, 60 s at 68°C, and 90 s at 72°C, and a final 5-min elongation
period at 72°C. The PCR product was purified using the Wizard SV gel and PCR clean-up system
(Promega). The amplified MetAP1Lm gene was then cloned into the XbaI restriction site of the
Leishmania expression vector p1RlHYG. The plR1HYG expression vector was kindly provided by
Stephen M. Beverley at Washington University, St. Louis, MO. The identification of the clone
MetAP1Lm/p1RlHYG was confirmed by DNA sequencing (DNA Analysis Core Facility, Border
Biomedical Research Center, El Paso, TX). L. major-luc promastigotes were transfected with 25µg
of MetAP1Lm/p1RlHYG. The transfected (LucMetAP1Lm/ p1RlHYG) parasites were plated in
M199 medium, 0.0005% hemin, 10% iFBS (Gibco), 50 ng/ml streptothricin (GoldBio), 1%
agarose, and incubated at 28°C. After 10 days, parasite colonies were observed, and an individual
colony (clone of parasites) was grown in liquid medium supplemented with 16 µg/ml hygromycin.
L. major LucMetAP1Lm /p1RlHYG transgenic parasites were used to confirm that the activity of
MetAP1Lm inhibitors (OJT006, OJT007, and OJT008) was on target.
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2.2.8 Measurement of reactive oxygen species levels
L. major promastigotes (1 × 106 cells/mL) were incubated for 24 h with 5D in a 96-well
clear bottom black microplate (BD Biosciences). Controls treated with 1% DMSO, 100 μM of
hydrogen peroxide (H2O2) as positive control, or M199 medium. After incubation period, 10 μM
of H2DCFDA (Thermo Fischer Scientific) (H2DCFDA/DMSO, 1 mg/mL) was added per well
followed by 20 min of incubation at 37 ◦C. Fluorescence was measured for an additional 7 h using
a fluorometer (Fluoroskan; Thermo Fisher Scientific, Waltham, MA, USA) at 527 nm using an
excitation wavelength of 485. For all measurements, basal fluorescence was subtracted.
2.2.9 Docking and binding site analysis of derivative 5D
The structure of trypanothione reductase bound to Flavin adenine dinucleotide (PDB ID:
2JK6) (120) were obtained from the Protein Data Bank. The Protein Preparation Wizard in Maestro
was used to minimize the protein structure, add hydrogens and charges, and find any missing
residues. The two-dimensional structures of 5D and Quinacrine Mustard, a recently experimentally
approved drug as a control, were drawn using the molecular structure editor ChemDraw Software
(PerkinElmer) and processed by LigPrep Schrödinger (Schrödinger) to generate the 3D structures.
Maestro’s SiteMap tool (Schrödinger) was used to predict the likely binding sites of trypanothione
reductase. The SiteMap tool uses a series of algorithm that generates a map of hydrophobic and
hydrophilic surfaces on the protein surface (121). Hydrophilic surface maps are divided into donor,
acceptor, and metal-binding regions. Five potential binding sites were identified with at least 15
site points. However, the top SiteMap was chosen to be the receptor grid.
2.2.10 Luciferase assay of Leishmania major overexpressing MetAP1Lm – Target validation
The inhibitors OJT006, OJT007, and OJT008 were screened in parallel with 1µ106/ml L.
major LucMetAP1Lm/p1RlHYG or wild-type L. major-luc promastigotes for 96h at 28°C. The
assay was performed using the same conditions described above for the luciferase viability assay.
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2.2.11 In vivo antiparasitic activity of MetAP1 inhibitors
Male BALB/c mice (6 to 8 weeks old) were injected in the left hind footpad with 50 µl of
L. major-luc metacyclic promastigotes in DMEM (1x106/ml) after purification by Ficoll step
gradient as previously described (122). After 18 days post-infection (dpi), animals were treated
orally (oral formulation of 70% deionized (DI) water and 30% PEG-400) with 20 mg/kg/day (100
µl/day) of OJT006, OJT007, or OJT008 or 4 mg/kg/ day intraperitoneally of reference drug
amphotericin B (Sigma-Aldrich) for a total of 13 days (n= 5 mice per group). Infection was
monitored by footpad lesion measurements using a digital caliper or by bioluminescence imaging
in an IVIS Lumina III in vivo imaging system (Perkin Elmer). Bioluminescence images were
acquired at 18, 25, and 31 dpi after administration of 200 µl of 150 mg/kg D-luciferin in phosphatebuffered saline (PBS; Gold Biotechnology) as previously described (123). After D-luciferin
injection, mice were kept conscious for 10 min to allow luciferin to be metabolized and circulate
and then anesthetized with 2.5% gaseous isoflurane and imaged after 5 additional minutes.
Luminescence data were analyzed using Living Image software (Perkin Elmer). Quantification of
bioluminescence per footpad is represented as radiance (photons per second per square centimeter
per steradian [p/s/cm2/sr]).
2.2.12 Parasite load by quantitative PCR.
At the experimental endpoint, mice were euthanized by CO2 overdose and the infected
footpads were harvested from all groups. Genomic DNA was extracted from 20 to 30 mg of tissue
using the high pure PCR template preparation kit (Roche), following the manufacture’s protocol.
Parasite footpad burden was determined by absolute quantification based on a standard DNA curve
ranging from 0.5 to 105 L. major parasite equivalents/ml. A standard curve was produced by
extracting DNA from a 20- to 30-mg tissue fragment spiked with 105 L. major promastigotes.
Amplification of a 120-bp fragment from kinetoplastid DNA was performed using 100 nM forward
primer

(5’-CTTTTCTGGTCCTCCGGGTAGG-3’),
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100

nM

reverse

primer

(5’-

CCACCCGGCCCTATTTTACACCAA-3’),

and

TaqMan

probe

(5’-FAM-

TTTCGCAGAACGCCCCTACCCGC-TAMRA-3’) (124). As an internal control, a linearized
pUC57 plasmid containing a sequence from Arabidopsis thaliana was spiked before all DNA
extractions as previously described (125). TaqMan chemistry allowed a 2-step temperature cycle.
PCR conditions were set at 50°C for 2 min, 94°C for 10 min, followed by 45 cycles at 94°C for 15
s and 55°C for 1min (124). Samples were run in triplicate in the StepOnePlus real-time PCR
System (Applied Biosystems), and parasite equivalents per 100 ng were plotted. All the conditions
were followed as previously described (62).
2.2.13 Toxicity monitoring and assessment.
Treatment toxicity was evaluated by monitoring mouse weight changes periodically.
Weight changes (grams) were normalized by subtracting from the mouse’s initial weight.
Moreover, blood was collected by cardiac puncture at the endpoint and serum obtained by
centrifugation at 2,000 rpm for 10 min. The levels of serum alanine aminotransferase (ALT) and
aspartate aminotransferase (AST) enzymes in OJT008-treated mice were measured according to
the manufacturer’s recommendations (ALT or AST activity kit; Sigma-Aldrich).
2.3 RESULTS
2.3.1 In Vitro anti-leishmanial activity of thiophene derivatives and MetAP1 inhibitors, and
their cytotoxicity
Nine thiophene derivatives (5A, 5B, 5C, 5D, 5E, 5F, 5G, 5H, and 5I) and eight MetAP1
inhibitors (OJT001, OJT002, OJT003, OJT004, OJT005, OJT006, OJT007, and OJT008) (Fig 2.1
and table 2.1) were tested to determine their effectiveness against the promastigote form of L.
major. First, parasites were incubated with each of the nine thiophene derivatives or eight
inhibitors for 72 h in the presence of increasing drug concentration (0.005 to 12.5 µM). The most
potent antileishmanial agents found were 5D, 5E, OJT006, OJT007, and OJT008, exhibiting low
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50% effective concentrations (EC50) of 0.09 µM, 0.78 µM, 0.6 µM, 0.38 µM, and 0.24 µM,
respectively, after incubation (table 2.2). Next, the cytotoxic effects of the best thiophene
derivatives (5D and 5E) and MetAP1 inhibitors (OJT006, OJT007, and OJT008) were determined
by HCIA to IPf after 48 h of treatment. None of the compounds displayed cytotoxicity against IPf
at concentrations up to 10 µM (table 2.2). Importantly, complete inhibition of extracellular
promastigotes of L. majorluc was detected at a low concentration. Therefore, a wide window of
selectivity (the selectivity indices [SI] were 310, 21.27, 131.6, 107.05, and 617.08 for 5D, 5E,
5OJT006, OJT007, and OJT008, respectively) between parasite and mammalian cell was observed
(table 2.2).

Figure 2.1 Chemical structures of the nine thiophene compounds.

Table 2.1 Structural classes of methionine aminopeptidase inhibitors
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Table 2.2 Antiparasitic activities of OJT and thiophene derivatives at 72 h in L. major
promastigotes and cytotoxicities of the compounds to intraperitoneal mouse
macrophages
Value ± estimated interval for:
Promastigotes
Macrophages
a
Compound
EC50 (µM)
CC50 (µM)b
SIc
OJT001
10.9 ± 1.3
<2.5
NAd
<2.5
NA
OJT002
11.96 ± 0.84
OJT003
14.36 ± 0.45
<2.5
NA
<2.5
NA
OJT004
3.36 ± 0.13
<2.5
NA
OJT005
6.8 ± 0.57
131.6
OJT006
~0.6
79 ± 2.34
OJT007
0.38 ± 0.006
40.58 ± 2.18
107.05
OJT008
~0.24
~148.1
617.08
5A
~0.3410
~10.4
30.5
<2.5
NA
5B
5.98 ± 1.72
<2.5
NA
5C
4.73 ± 0.69
5D
0.09 ± 0.02
27.89 ± 3.19
310
5E
0.78 ± 0.11
16.59 ± 1.52
16.59
5F
>12.5
<2.5
NA
<2.5
NA
5G
>12.5
5H
3.05 ± 0.47
<2.5
NA
<2.5
NA
5I
5.5 ± 1.8
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a

EC50, median effective concentration. Measure of antiparasitic activity against L. major

promastigotes.
b

CC50, median cytotoxic concentration. Measure of cytotoxicity in mammalian cells

(intraperitoneal mouse macrophages [IP f]).
c

SI, selectivity index (CC50/EC50).

d

NA, not applicable.

2.3.2 In vitro efficacy of compounds against intracellular amastigotes
The most potent thiophene derivatives (5D and 5E) and MetAP1 inhibitors (OJT006,
OJT007, and OJT008) were chosen to further study their effects against intracellular amastigotes
proliferated inside IPf. Since we are interested in the potential antiproliferative properties of these
compounds, we first incubated L. major-luc-infected BALB/c IPf for 48 h with 5D or 5E, and
OJT006, OJT007, or OJT008 treatment. We observed in the thiophene derivatives that at a
concentration of 0.625 µM were able to inhibit the proliferation of intracellular amastigotes by
more than 75% and 50% for 5D and 5E, respectively (Fig 2.2). For the MetAP1 inhibitors, it was
observed that at a concentration of 0.312 µM, OJT006, OJT007, and OJT008 were able to inhibit
the proliferation of intracellular amastigotes by approximately 80%, 90%, and 85%, respectively
(Fig 2.3). The assay Z factor was 0.5, indicating this is a satisfactory assay. Taken together, these
results indicated that 5D, 5E, OJT006, OJT007, and OJT008 have high antileishmanial effects in
both the extracellular and intracellular forms of the parasite with no cytotoxicity to mammalian
cells. Thus, thiophene derivative 5D was chosen for elucidation of the mechanism of action while
OJT006, OJT007, and OJT008 were further selected for evaluation in a preclinical in vivo model
of CL.

35

Figure 2.2. Thiophene activity in amastigotes
(3) High content imaging assay (HCIA) analysis of intraperitoneal mouse macrophages (IPΦ)
infected with L. major-luc amastigotes, followed by treatment with 5D or 5E from 0.63 to
10 μM for 48 h. Controls included untreated, 1% DMSO, amphotericin B (amp B) at 5
μM, or parent drug 5A. 48 h. Data are represented as the percentage (%) of infected IPΦ
with three or more amastigotes per cell. Note: Data for 5A at concentration 5 and 10 μM
were not generated because 5A was cytotoxic for IPΦ at such concentration. (B)
Representative monochromatic images of infected IPΦ with L. major after 48 h treatment
with 5D or 5E at 2.5 μM, amp B (5 μM), or 1% DMSO.
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Figure 2.3 MetAP1 inhibitors OJT006, OJT007, and OJT008 reduced the intracellular
proliferation of L. majorLuc amastigotes.
Data from high-content imaging assay (HCIA) analysis of intraperitoneal mouse macro- phages
(IP f) infected with L. majorLuc metacyclic promastigotes and treated with OJT006, OJT007, or
OJT008 inhibitor from 0.312 µM to 20 µM for 48 h are shown. Controls were treated with 1%
DMSO (drug diluent control) or amphotericin B (Amp B) at 5 µM (reference drug; positive
control). Data are represented as the percentages (%) of infected IPf with 5 or more amastigotes
per cell. Error bars indicate standard errors of the means (SEM).
2.3.3 Mechanism of action of compound 5D
Based on our previous study (97), it was hypothesized that 5D may induce parasite death
through the production of ROS. Thus, 2×106/mL L. majorLuc promastigotes were incubated with
5D (EC50 0.09 μM). After 24 h, ROS levels were measured by the addition of 10 μM of the cellpermeable permeable dye H2DCFDA, and fluorescence was monitor for an additional 7 h using a
fluorometer. As expected, ROS levels in 5D treated parasites were 14.5-fold higher compared to
vehicle control 1% DMSO (Fig 2.4).
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Figure 2.4 ROS activity generated by compound 5D in L. major
Generation of reactive oxygen species in L. major treated for 31 h with 5D at 0.90 μM (EC50).
Values shown are the mean and standard error of five different replicates minus basal fluorescence.
Control treated with 1% DMSO or hydrogen peroxide (H2O2) at 100 μM.
2.3.4 Docking studies of thiophene derivative 5D
Next, to determine the possible molecular mechanism responsible for the antileishmanial
activity of 5D, docking studies on TryR from L. infantum (PDB id: 2JK6) were performed. Using
Glide Standard Precision (126) and Extra Precision (XP), Rigid Receptor Docking analysis of
control (Quinacrine Mustard) and 5D was performed. The 3D ligand structures were docked
against the best potential binding site of 2JK6. Glide SP and XP only accounts for the ligand being
dynamic. However, the protein remains rigid. Docking box coordinates and dimensions remained
all at default (20 x 20 x 20 Å). Glide XP gives an output of a docking score, which was analyzed
by the lowest number, or whichever is more negative to be the highest scoring ligand. The docking
results, summarized in Table 2.3, showed the control (Quinacrine Mustard) with higher binding
affinity than 5D in both SP and XP. However, the XP docking score did not differ by much,
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indicating more rigorous docking analysis is needed. Thus, both ligands were taken to
Schrodinger’s Flexible receptor docking.
Schrodinger IFD protocol for all IFD jobs was used. The IFD program makes use of both
Glide (for docking) and Prime (for protein structure modeling). The combination of the two
software’s allows a more accurate ligand binding calculation. We performed the re-docking with
Glide XP for the refined docking results (127). The IFD data presented in Table 2.3 showed that
our lead molecule 5D had a better binding affinity. Docking scores from Rigid Receptor Docking
and Flexible Receptor differed significantly. This is accounted for the protein dynamic movement
during drug binding in IFD. Furthermore, figure 2.5 A and B introduce the IFD binding pocket of
the protein-ligand complex. Figure 2.5 A shows our lead molecule 5D which displays hydrogen
bond interactions with SER 1632, ARG 287, VAL 55, and also with CYS 57. 5D also exhibits pcation interaction with residue ARG 287. Quinacrine Mustard interacted with a new set of residues
and showed only two hydrogen bonds between MET 333 and ALA 365 (Fig 2.5 B). The control
also formed salt bridges with ASP 327 as well as GLU 202. p-p and p-cation interaction was also
shown between TYR 198 and LYS 60, respectively. These results provided evidence that the
possible mechanism of action of 5D may be through the inhibition of TryR, an essential enzyme
to the thiol metabolism of the parasite (128, 129), and promising chemotherapeutic target against
leishmaniasis (130).
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Table 2.3 In silico study of 5D and control Quinacrine Mustard

Figure 2.5 Trypanothione Reductase from L. infantum (PDB: 2JK6) Protein–ligand complex of
Induced Fit Docking (IFD)
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(3) ligand interaction diagram of 5D in complex with 2JK6 and 2D ligand interaction and (B)
ligand interaction diagram of Quinacrine Mustard in complex with 2JK6 and 2D ligand
interaction.
2.3.5 MetAP1 inhibitory activity on target
To determine whether our three lead candidates were specific against MetAP1Lm, we first
treated 1x106 transgenic promastigotes/ml (MetAP1LmLuc/p1RlHYG, a transgenic parasite that
simultaneously expresses luciferase and overexpresses MetAP1Lm) or wild-type parasites for 96 h
with OJT006, OJT007, or OJT008. As expected, the antileishmanial activity of amphotericin B
(reference drug; control) was not altered in the transfected LucMetAP1Lm/p1RlHYG parasites
(Fig 2.6 B). In contrast, increases of more than 10-fold were observed in the EC50 values of
OJT006, OJT007, and OJT008 when tested against transfected LucMetAP1Lm promastigotes
compared to the values for treatment of wild-type L. majorLuc (Fig 2.6 A and B). These data
strongly suggest that OJT006, OJT007, and OJT008 successfully inhibited MetAP1Lm, acting on
target.

Figure 2.6 Action of MetAP1 inhibitors OJT006, OJT007, and OJT008 is on target.
(3) Data from viability assay of L. majorLuc promastigotes (wild type) treated with inhibitor
OJT006, OJT007, or OJT008 for 96 h in a concentration range of 0.13 μM to 3.12 μM are
shown. (B) Data from viability assay of transfected (MetAP1LmLuc/p1RlHYG) L. major
promastigotes treated with the OJT006, OJT007, or OJT008 inhibitors in a concentration
41

range of 0.13 μM to 3.12 μM for 96 h are shown. Controls were treated with 1% DMSO
(diluent drug control) or amphotericin B (Amp B) at 5 μM (reference drug). Error bars
indicate SEM.
2.3.6 In vivo activity of MetAP1 inhibitors against L. major infection in the murine model
The in vivo activities of MetAP1 inhibitors OJT006, OJT007, and OJT008 were
characterized in L. majorLuc-infected BALB/c mice. First, we evaluated the oral drug
administration of different formulations by assessing their antiparasitic activities and potential
toxicity in mice. Mice treated with a formulation in 70% deionized (DI) water–30% polyethylene
glycol 400 (PEG 400) showed it to be well tolerated, with no weight loss observed, maintaining
the antiparasitic activity of OJT006, OJT007, or OJT008 (Fig 2.7 A and B). Therefore, this
formulation was selected for subsequent experiments. Next, BALB/c mice (n=5) were infected,
and after 18days post-infection (dpi), mice were orally treated at 20 mg/kg of body weight/day
with OJT006, OJT007, or OJT008. After 13 consecutive days of treatment, inhibitors OJT006 and
OJT007 were shown to have lower efficacies than OJT008. However, all showed decreases in the
lesion sizes in treated mice compared to the effect of the placebo control (Fig 2.8). Nevertheless,
small lesion sizes were observed through the course of the infection in OJT008-treated mice (Fig
2.8). To further study and corroborate the efficacy of OJT008 in the preclinical model, we decided
to follow the infection during the course of treatment, using in vivo bioluminescence imaging.
Thus, BALB/c mice (n=5) were infected and treated using the same conditions as before, and
images were acquired at 18, 25, and 31 dpi (Fig 2.9 A and B). Similarly, to the results for
amphotericin B (reference drug), OJT008 significantly (P<0.0001) decreased the parasite’s
bioluminescence signal (Fig 2.9 A and B). Furthermore, quantitative PCR (qPCR) was performed
to analyze the parasite burden of mice treated with OJT008. As expected, compared to the parasite
loads in the placebo group, OJT008-treated mice had a significant (P<0.01) reduction in parasite
load, by 86% (Fig 2.9 C). Taken together, these findings suggest that OJT008 successfully reduced
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and controlled L. major infection in a preclinical murine model of CL, representing the therapeutic
potential of the inhibitor.

Figure 2.7 Pre-assessment of therapeutic dose and formulation toxicity.
(3) Lesion size of L. majorLuc infected-treated BALB/c mice treated with 8 mg/kg/day with
OJT006, OJT007, OJT008 diluted in 70% DI water/30% PEG-400 (formulation). (B)
Assessment of formulation toxicity by weight change (grams) in BALB/c mice infected
and treated with OJT006, OJT007, OJT008.
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Figure 2.8 Lesion size of L. majorLuc infected-treated BALB/c mice with 20 mg/kg/day with
OJT006, OJT007, or OJT008.

Figure 2.9 Oral treatment with OJT008 significantly reduced the parasitic burden caused by L.
majorLuc infection.
(3) Quantification of parasite bioluminescence emitted in BALB/c mouse footpads infected
with L. majorLuc metacyclic promastigotes and treated with 20 mg/kg/day of OJT008, 4
mg/kg/day of amphotericin B (Amp B; reference drug group), or placebo (PBS; control
group). Two-way ANOVA with Dunnett’s multiple-comparison test (compared to placebo
group). *, P < 0.05; **, P < 0.01; ***, P < 0.0001. Error bars indicate SEM. (B)
Representative images of in vivo bioluminescence acquired at 1, 18, 25, and 31 dpi from
L. majorLuc-infected BALB/c mice treated with OJT008, Amp B, or placebo. (C)
Quantification of parasitic load (parasite equivalents/100 ng) by qPCR at experimental
endpoint (31 dpi). One-way ANOVA (compared to placebo; control group). **, P < 0.01.
Error bars indicate SEM.
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2.3.7 Toxicity analysis of OJT008 in the murine model of CL
Elevated serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase
(AST) enzymes are recognized as markers for cardiac and hepatic damage, respectively (131). As
observed in the experiments whose results are shown in Fig. 2.10 A and B, serum AST and ALT
levels of mice treated with OJT008 were not elevated and were similar to those in the placebo
group, indicative of drug safety. These results were further supported by the observation that the
mouse weights in the OJT008-treated group were not statistically different from the weights in the
placebo-treated control group (Fig. 2.10 C). Additionally, OJT008 caused no changes in the
behavior, appetite, waste elimination, appearance, or survival of treated mice compared to these
parameters in placebo- and amphotericin B-treated animals (Fig. 2.10 C). These results
demonstrate the oral safety of the MetAP1 inhibitor OJT008 in a preclinical murine model of CL.

Figure 2.10 OJT008 is nontoxic in vivo.
(A and B) Evaluation of systemic toxicity by serum levels of alanine aminotransferase (ALT) (A)
and aspartate aminotransferase (AST) (B) in L. major-luc-infected BALB/c mice dosed with 20
mg/kg/day of OJT008, 4 mg/kg/day of Amp B, or placebo (PBS). Pooled serum samples were
collected at 31 dpi (endpoint). Positive control [C (+)] was provided by the kit’s manufacturer
(Sigma-Aldrich). Data are represented as units/ml (U/ml). Ordinary one-way ANOVA with
Dunnett’s multiple-comparison test (compared to positive control). *, P < 0.05; **, P < 0.01; ***,
P < 0.001; ****, P < 0.0001. (C) Assessment of treatment toxicity by weight change (grams) in L.
major-luc-infected BALB/c mice treated with 20 mg/kg/day of OJT008, Amp B, or placebo (PBS).
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Two-way ANOVA with Dunnett’s multiple-comparison test (compared to PBS group). *, P < 0.05;
**, P < 0.01; ***, P < 0.001; ****, P < 0.0001. Error bars indicate SEM.
2.4 DISCUSSION AND FUTURE WORK
Despite the advances in understanding the protozoan parasite L. major, CL continues to
cause significant morbidity. The drugs available to treat this disease (i.e., pentavalent antimonials
and amphotericin B) are old, limited in efficacy, and present severe side effects, and drug resistance
continues to be reported. Consequently, there is an urgent need for new chemotherapeutic
approaches to treat CL (132). Herein, we present data that demonstrate the potential success of
novel thiophene derivatives and MetAP1 inhibitors as chemotherapeutic agents against L. major
infection.
2.4.1 Thiophene derivatives discussion and future work
Thiophenes derivatives are known for their therapeutic applications and have shown
promising results to treat different types of cancer, degenerative diseases, HIV, and malaria (133140). Thus, here we evaluated the anti-leishmania activity and selectivity against L. major of nine
thiophene derivatives, and potential MOA was elucidated for the best candidate, 5D.
Thiophene derivatives 5A, 5D, and 5E exhibited potent parasitic activity against L. majorLuc
promastigotes. Experimental models involving macrophages are ideal to study leishmaniasis since
they are the major host cell for Leishmania spp. (141). Thus, our three best candidates were further
evaluated against the most important form of the parasite, amastigotes, in an in vitro infection
model of murine macrophages. In this case, 5D presented the best anti-leishmanial activity by
decreasing the proliferation of the parasite by 80%.
The in vitro toxicity of 5D and 5E was evaluated towards IPj. Our best two compounds
were safer for the two cytotoxic models than the reference drug, amphotericin B, which is already
known for its cytotoxic effects (142). Even though amphotericin B presented similar activity as
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5D against promastigotes and amastigotes, this result further supports the application of 5D and
5E as anti-leishmanial agents. Furthermore, the selectivity presented by 5D was remarkably higher
than the parental compound 5A (10-fold higher), demonstrating the success to increase the antileishmanial activity and reduced cytotoxicity effects when compared to our previously reported
aryl alkylamine type-compound.
Next, we studied the potential MOA of derivative 5D. ROS can be generated in response
to some drugs, resulting in destruction of cellular macromolecular components inducing cell death
by affecting parasite mitochondrial function (143, 144). Here, we observed that 5D induced ROS
production in L. major promastigotes after 31 h of treatment. The redox homeostasis in Leishmania
is achieved through the activity of several superoxide dismutases, heme peroxidases, as well as of
a series of thiol-containing proteins that directly or indirectly depend on trypanothione reductase
(129, 145). In this regard, the trypanothione metabolism is unique to trypanosomatids and its main
detoxification pathway (146). This pathway protects parasites from oxidative stress and
participates in several cellular processes that are carried out by glutathione in other organisms.
Moreover, there are several trypanothione-dependent pathways that include enzymes such as
tryparedoxin peroxidase (detoxication of hydroperoxide), ascorbate peroxidase (homeostasis of
ascorbate), ribonucleotide reductase (synthesis of DNA precursors), and others (147, 148). With
this idea on mind, we decided to explore in silico docking analysis to assess the possibility of L.
major TryR as the target of 5D. Moreover, our results suggested that TryR interacts with 5D,
however we do not exclude the possibility that other redox metabolism enzymes could be also
targeted by compound.
In conclusion, to discover new chemotherapy agents against leishmaniasis, we efficiently
synthetized nine thiophene type-compounds including 5A, following a two-step synthesis from
low-priced commercially available starting materials. We then showed that our novel thiophene
type-compounds possess high in vitro antileishmanial activity. Based on our SAR study, 5D analog
was selected as the most promising lead compound among this library with excellent antiparasitic
and S.I. Furthermore, 5D may act against trypanothione metabolism, followed by the production
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of ROS in the parasite; nevertheless, biological studies with recombinant TryR enzyme needs to
be performed to further support this assumption. Overall, 5D represents a potential
chemotherapeutic agent for the treatment of leishmaniasis, and further evaluation in a pre-clinical
mouse model of cutaneous leishmaniasis is being planned.
2.4.2 MetAP1 inhibitors discussion and future work
MetAP1 is a metalloprotease that removes the N-terminal methionine from proteins and
peptides, a process involved in the highly conserved N-terminal methionine excision (NME)
pathway (101). Since NME is an essential process in both prokaryotes and eukaryotes (104, 149),
inhibitors of MetAP have been suggested as novel chemotherapeutic agents against different forms
of cancer and bacterial, fungal, and parasitic infections (107, 150). Moreover, it has been reported
that deletion of MetAP1 in yeast and other eukaryotic cells is detrimental and leads to cell death
(117, 151, 152). Nonetheless, despite the obvious importance of this metalloprotease in L. major,
insufficient effort has been taken in exploiting MetAP1 as a drug target for CL.
A screening of 175,000 diverse small molecules conducted by Olaleye et al. led to the
discovery of eight potent MetAP1 inhibitors (OJT001 to OJT008). Treatment of L. majorLuc
promastigotes and intracellular amastigotes with inhibitors OJT001 to OJT008 revealed three
potent MetAP1 inhibitors, OJT006, OJT007, and OJT008, with EC50s in the low range of 0.243
µM to 0.640 µM. Interestingly, although the first five hydroxyquinoline compounds (OJT001 to
OJT005), with similar pharmacophores, have been reported to have potent activity against M.
tuberculosis MetAP1 and/or antimycobacterial activity (111), they were not potent against L.
major promastigotes, while compounds OJT006, OJT007, and OJT008, with three different novel
pharmacophores, showed potent activity. These observations suggest the enzyme specificity and
selective toxicity of the MetAP1 inhibitors.
In addition, we have demonstrated that the antiparasitic activity observed for the inhibitors
is due to a specific on-target effect by overexpressing MetAP1. We observed a 10-fold increase in

48

resistance to the antiparasitic activity of the compounds compared to the drug resistance of wildtype L. majorLuc. Therefore, we can conclude that since there is an excess of MetAP1 enzyme on
the transgenic parasites, a higher concentration of the drugs is required to achieve a similar
antiparasitic effect. Similarly, these effects were previously described in an M. tuberculosis model
by Olaleye et al. (107). These data provide evidence that the OJT006, OJT007, and OJT008
compounds specifically inhibit MetAP1 from L. majorLuc.
Drug accessibility and parenteral administration are two of the main reasons for treatment
interruption for leishmaniasis (5, 93). Several reports show that patients with conditions ranging
from cancer to autoimmune and infectious diseases have an inclination toward oral chemotherapy
administration rather than intravenous administration (153-155). Here, we present evidence of
potent oral efficacy of MetAP1 inhibitor OJT008 in a preclinical mouse model of CL. OJT008
significantly decreased the parasite load, by 86%, as shown by bioluminescence assay and qPCR.
More importantly, OJT008 did not generate adverse or toxic effects in treated infected BALB/c
mice, as observed by the low systemic levels of AST and ALT that were measured. Furthermore,
these data correlated with no significant weight loss and no behavior changes during the course of
treatment. Given these findings, we propose the MetAP1 inhibitor OJT008 for further preclinical
studies as a novel chemotherapy agent, representing an excellent candidate for the oral treatment
of CL.
To summarize, we validate MetAP1Lm as a target for the development of novel
antileishmanial drugs. We have discovered three (OJT006, OJT007, and OJT008) novel smallmolecule inhibitors of MetAP1 with diverse pharmacophores for potential development of agents
for CL treatment. This is the first report of a new pharmacophore targeting L. major-specific
MetAP1 (MetAP1Lm), in inhibitor OJT008, with significant antileishmanial activity in vitro and in
vivo. Further delivery experiments are planned, seeking to improve the antileishmanial activity of
OJT008. Our discovery of three new pharmacophores as potent MetAP1Lm inhibitors makes these
pharmacophores and the MetAP1Lm target an attractive combination for further optimization. In
addition, structure-activity relationships and X-ray crystallography structure studies will accelerate
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the rational design and synthesis of more potent MetAP1Lm inhibitors. Furthermore, these
inhibitors could be used as chemical probes or tools in the future to better understand the
physiologic relevance of MetAP1Lm in N-terminal methionine excision, as well as the essentiality
and substrate specificity of this class of enzymes in L. major.
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Chapter 3: Characterization and evaluation of a-Gal containing
glycosylphosphatidylinositol anchored-proteins (GPI-AP) from Leishmania spp.

3.1 INTRODUCTION
Protozoan parasites of the genus Leishmania cause a number of important diseases in
humans. These diseases are defined by the location of the parasite in the infected tissue: cutaneous
(CL), mucocutaneous (MCL) and visceral (VL) (3). The leishmaniasis are endemic in large areas
of the tropics, subtropics and Mediterranean basin (2). There are around 350 million people at risk
and around 12 million cases, with an estimated worldwide annual incidence of 0.7–1.2 million
cases of CL and 0.2–0.4 million cases of VL (1). Hence, Leishmaniases constitute a serious world
health problem with an increasing burden over the last decades, and it is among the seven most
important tropical disease (4, 156). Currently, there is no commercially available preventive or
therapeutic human vaccine for either forms of the disease (157). Furthermore, infected patients
rely on expensive and highly toxic drugs, which are costly and have become ineffective in some
areas due to emerging resistant parasite strains (93). Additionally, there is a need for molecular
biomarkers for assessment of treatment and diagnosis that are more sensitive and specific to the
different clinical forms (42).
Leishmania parasites undergo a complex life cycle, alternating between the insect vector
sandfly and the mammalian hosts. These occurs as extracellular promastigotes (PR) in the
digestive tract of the sandfly that transitions into an infective metacyclic promastigote (MP) form
that migrate to the proboscis of the insect vector. Once MP are injected into the skin of the
mammalian host and infect host macrophages, they transform into obligate intracellular
amastigotes (AM) in the phagolysosome. Surface molecules are involved in mediating these hostparasite interactions and in protecting the parasite in each of these environments (23). Additionally,
the surface of Leishmania parasites is coated by a glycocalyx that is rich in glycoproteins and
glycolipids that are anchor to the plasma membrane via glycosylphosphatidylinositol (GPI) and
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this includes glycolipids such as glycoinositol phospholipids (GIPL) and lipophosphoglycan
(LPG), and glycoproteins such as proteophosphoglycans (PPG) and GPI anchor proteins (24).
Among these glycoconjugates, GPI-AP are highly glycosylated, a post-translational modification
of proteins whereby a carbohydrate moiety (glycan) is attached covalently to the peptide backbone
of a protein in very diverse ways and it is carried out by specific enzymes termed
glycosyltransferases (158). In Leishmania parasites and other microorganism, highly glycosylated
GPI-AP have been shown to be crucial for development, growth, function, survival and hostpathogen interaction (23-25, 159-161).
In this study, we report the purification, characterization and evaluation of highly
immunogenic α-gal GPI-AP that can be used as vaccine candidates or as biomarkers to assess
diagnosis and treatment against leishmaniasis. In humans, the gene α1,3-galactosyltransferase
(α1,3GalT) is inactive (49). Thus, terminal, non-reducing and linear α-Gal epitopes are absent and,
therefore, highly immunogenic to humans and Old-World nonhuman primates. Therefore, healthy
human individuals normally produce anti-α-Gal antibodies (also known as normal anti-Gal
antibodies) against α-Gal epitopes (52). Here, we used L. major (for CL), L. guyanensis (for CL
and MCL), L. braziliensis (for MCL), and L. donovani (for VL) to purify α-gal containing GPIAP. These purified glycoproteins will then be analyzed by ELISA, western blot, silver stain,
MALDI-TOF and mass spectrometry for fully characterization and evaluation.
3.2 MATERIALS AND METHODS
3.2.1 Leishmania cell culture
Promastigotes of L. major strain Friedlin V1 were grown at 28 oC in M199 with Earle’s
salts and L-glutamine (Sigma-Aldrich) supplemented with 15 mM HEPES (Gibco), 10 mM
adenine (Sigma-Aldrich), 1 µg/mL D-biotin (MP biomedicals), 5 µg/mL hemin (Sigma-Aldrich)
in 50% triethanolamine (Sigma-Aldrich), 10% inactivated fetal bovine serum (iFBS, Gibco), 2
µg/mL L-biopterin (Enzo Life sciences) and 50 U/mL-50 µg/mL penicillin/streptomycin (Gibco)
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as previously described (162). Promastigotes of Vianna sp. (L. braziliensis clones 1174 Cali, LEM
3874, LEM 2870, and LCTP 13330 and L. guyanensis M4147 and LEM 1684) were grown 28 oC
in freshly prepared Schneider’s Insect Medium (Sigma-Aldrich) following the manufacture’s
recommendation and supplemented with 1 µg/mL hemin in 50% triethanolamine, 0.1 mM adenine
in 50 mM HEPES, 2 µg/mL L-biopterin, 10% iFBS and 50 U/mL-50 µg/mL
penicillin/streptomycin as previously described (163). Promastigotes and axenic amastigotes of L.
donovani clone Ld1S were culture in M199 with Hank’s salts and L-glutamine (Sigma-Aldrich)
as previously described (164). Briefly, promastigotes were culture at 28 oC in M199 supplemented
with 25 mM HEPES, 12 mM NaHCO3, 50 U/mL-50 µg/mL penicillin/streptomycin, 2 mM Lglutamine (Gibco), 1X RPMI vitamin mix (Sigma-Aldrich), 10 µM folic acid (Sigma-Aldrich),
100 µM adenine, 5 µg/mL hemin in 50% triethanolamine, 10% iFBS and adjusted to pH 6.9.
Amastigotes were culture at 37 oC, 5% CO2 in M199 supplemented with 28 mM MES (SigmaAldrich), 1X RPMI amino acid mix (Sigma-Aldrich), 50 U/mL-50 µg/mL penicillin/streptomycin,
4 mM L-glutamine, 1X RPMI vitamin mix, 10 µM folic acid, 100 µM adenine, 5 µg/mL hemin in
50% triethanolamine, 25.6% iFBS and adjusted to pH 5.6. L. donovani parasites were converted
between forms by diluting cultures 1:50 into appropriate media, every 3-4 days. The volume of
media in amastigotes culture must be maintained at low levels (max 5 mL in T25 flask or 15 mL
in T75) to ensure proper aeration. All Leishmania culture were not kept longer than 7 passages.
3.2.2. Parasite isolation
Promastigotes (PR) and metacyclic promastigotes (MP) were isolated for each Leishmania
sp. using different methodologies. L. major Luc PR and MP were isolated by Ficoll gradient as
previously described (122) as follow: 800 mL of stationary phase (4-5 days old culture) L. major
Luc were centrifuged at 2600 g for 15 min at 4 oC and resulting pellet was resuspended in 30 mL
of Dulbecco’s modified Eagle’s medium (DMEM, Corning) and incubated for 30 min at room
temperature. After incubation, this suspension was layered on top of a step gradient in a 175-mL
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Falcon centrifuge tube containing 30 mL of 10% Ficoll solution (15 mL of 20% Ficoll, 6 mL of
1X M199 without serum, and 9 mL of sterile H2O) that was layered on top of 30 mL of a 20%
Ficoll solution (Sigma-Aldrich). The gradient was centrifuged at 1300 g for 10 min at room
temperature. MP were recovered from the top and 10% interface and centrifuged at 2600 g for 15
min at 4 oC. PR were recovered from the 10% Ficoll step and the 20% interface and centrifuged at
1600 g for 10 min at 4 oC.
PR and MP of L. braziliensis and L. guyanensis were isolated by lectin mediated
agglutination. PR and MP of L. braziliensis were isolated as previously described (165). Briefly,
800 mL of stationary phase (5-6 days old) L. braziliensis parasites were centrifuge at 2760 g for
15 min at 4 oC and resulting pellet was resuspended in 15 mL of phosphate buffer solution
(PBS), pH 7.4 supplemented with 125 µg/mL of Lens culinaris lectin (Bioworld) and incubated
for 30 min rocking at room temperature. After incubation, the parasite suspension was
centrifuged at 20 g for 5 min at 4 oC to sediment agglutinated parasites. The supernatant
contained PR and it was centrifuged at 2300 g for 10 min at 4 oC. The pellet contained MP and it
was resuspended in 1 mL of PBS and centrifuged at 2760 g for 15 min at 4 oC. PR and MP of L.
guyanensis were isolated as previously described (166). Briefly, 800 mL of stationary phase (5-6
days old) L. guyanensis parasites were centrifuge at 3000 g for 15 min at 4 oC and resulting pellet
was resuspended in 15 mL of PBS, pH 7.4 supplemented with 100 µg/mL of Bauhinia purpurea
lectin (Vector Labs) and incubated for 30 min rocking at room temperature. After incubation, the
parasite suspension was centrifuged at 40 g for 5 min at 4 oC to sediment agglutinated parasites.
The supernatant contained MP and it was centrifuged at 3000 g for 15 min at 4 oC. The pellet
contained PR and it was resuspended in 1 mL of PBS and centrifuged at 2400 g for 10 min at 4
o

C.
In the case of L. donovani Ld1S, PR and MP were not possible to be isolated from

cultures since the available method requires 6-7 days old culture and our particular strain Ld1S
cannot be maintain in the stationary phase longer than 4 days because they start dying quickly.
Therefore, only PR and amastigotes (AM) were used for L. donovani Ld1S. PR were collected
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by centrifuging 800 mL of log-phase (2-3 days old) L. donovani Ld1S culture at 2200 g for 10
min at 4 oC. AM were collected by centrifugation 800 mL of amastigotes culture (prepared as
previously above) at 3300 g for 15 min at 4 oC.
All parasite isolations were collected in MeOH-rinsed borosilicate glass tubes, with
polytetrafluoroethylene (PTFE)-lined screwcap, 25-mm O.D., 150-mm length and were
centrifuged at 3300 g for 10 min at 4 oC. Pellets were placed at -80 oC for 40 min and lyophilized
overnight.
3.2.3 Extraction of glycosylphosphatidylinositol anchored proteins (GPI-AP)
GPI-AP from lyophilized Leishmania sp.

parasites were extracted in MeOH-rinsed

borosilicate glass tubes, with polytetrafluoroethylene (PTFE)-lined screwcap as described
previously for T. cruzi (59, 167, 168) with minor modifications. Briefly, lyophilized parasites were
delipidated by adding 2 mL CHCl3, 4 mL MeOH, and 1.6 mL ice-cold H2O (C:M:W, 1:2:0.8,
v/v/v) vortex for 2 min vigorously and centrifuged for 10 min at 2000 g, 4 oC (This process was
repeated two more times). The resulting supernatants (enriched with lipids) were pooled and
transferred to a new glass tube with PTFE-lined cap. To the partially delipidated pellet, 2 mL
CHCl3 and 4 mL MeOH (C:M, 1:2, v/v) was added, vortexed for 2 min and centrifuged for 10 min
at 2000 g, 4 oC twice. The resulting supernatants were transferred to the tube containing the lipid
(organic) extract. To the C:M (2:1, v/v)-delipidated pellet, 2 mL CHCl3, 4 mL MeOH, and 1.6 mL
ice-cold H2O (C:M:W, 1:2:0.8, v/v/v) were added, vortexed for 2 min and centrifuged for 10 min
at 2000 g, 4 oC and supernatant was transferred to the lipid (organic). The C:M/C:M:W-delipidated
pellet and lipid extract were dried under a low, constant stream of nitrogen gas. Once the
delipidated pellets were dried, 4 mL of 9%1-BuOH (obtained from vigorously mixing 1:1 1-BuOH
and H2O, let it rest overnight and recovering the upper phase which contains 9% 1-BuOH, the
remaining lower phase contains 91% 1-BuOH) was added and incubated rocking at 4 oC for 72 h.
After incubation, samples were centrifuged for 10 min at 2500 g, 4 oC. Supernatant (enriched in
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GPI-AP) was removed and transfer to a new glass tube with PTFE-lined cap. Finally, GPI-AP
were further partitioned from any remaining phospholipid and/or glycolipid (GIPL or LPG not
extracted by C:M:W and C:M) by adding about the same remaining volume with 91% 1-BuOH,
centrifuged for 10 min at 2000 g, 4 oC twice. Three layers form after centrifugation: upper phase
(91% 1-BuOH fraction) enriched with GIPL and LPG, and lower phase and interphase (9% 1BuOH fraction) enriched with GPI-AP. Both fractions were transferred to separate glass tubes with
PTFE-lined cap. The 9% 1-BuOH fraction was lyophilized, and the 91% 1-BuOH fraction was
dried under a constant nitrogen gas stream.
3.2.4 Glycoprotein quantification by Myo-inositol quantification by gas chromatographymass spectrometry (GC-MS)
Myo-inositol from GPI-AP was quantified by GC-MS as previously described (169).
Briefly, reactions were prepared in heat-cleaned (500 C) glass capillary tubes and flamed sealed
at one end to form a microtube. First, 10 µL of GPI-AP sample was pre-mixed with 20 pmol D6
myo-inositol (Sigma) internal standard and placed inside the flame-sealed capillary microtube. A
standard curve was also prepared for quantification using 2 pmol, 1 pmol, 0.1 pmol, and 0.001
pmol and 0.0001 pmol D6 myo-inositol. All samples (GPI-AP and standards) were dried by speedvac. Once dried, 6 M HCl were added and microtube flame-sealed at the other end under slight
vacuum. Sealed microtubes were hydrolyzed in a heat block at 110 C for 16-24 h. After
hydrolyzation, glass microtubes were open with a glass cutter at the top and samples were dried
by speed-vac. Residual HCl was removed by co-evaporation by speed-vac with 50 µL water and
finally sample residues were rehydrated with 20 µL MeOH followed by speed-vac. Right before
injection into the GC-MS, samples were derivatized with 15 µL TMS (freshly prepared with 50
µL l-trimethylchlorosilane and 150 µL hexamethyldisilazane to 1000 µL dry pyridine [1:3:20,
v/v/v]) and microtubes were sealed with Teflon tape for at least 30 min. 1 µL of sample was
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injected into the GC-MS and values were calculated by comparing them to the D6 myo-inositol
standard curve.
3.2.5 Chemiluminescent enzyme-linked immunosorbent assay (CL ELISA)
CL-ELISA (170) was performed for screening of GPI-AP samples and fractions reactivity
for a-gal epitopes with biotinylated Bandeiraea simplicifolia isolectin 4 (IB4) lectin (Vector labs),
or reactivity with serum pools of infected patients with leishmaniasis. Briefly, 96-well Nunc high
protein-binding capacity MaxiSorp white microplate (Thermo Scientific) were coated overnight at
4 oC with different concentration of GPI-AP per well in 50 μL of 200 mM carbonate-bicarbonate
buffer, pH 9.6 (CBC buffer). Plates were blocked with 200 μL 1% BSA-PBS (BSA, SigmaAldrich) for 1 h at 37 oC before washing three times with PBS-0.05% Tween 20 (Sigma-Aldrich)
(PBS-T). Then, plates were incubated with 10 µg/mL biotinylated IB4 in 1% BSA-PBS for 1 h at
37 oC. After incubation, 50 μL of 1:5000 dilution 1% BSA-PBS-T of High Sensitivity
NeutrAvidin-horseradish peroxidase (Invitrogen) in PBS was added and plates were incubated for
30 min at 37 oC. Plates were washed three times between steps with PBS-T, except before blocking.
The reaction was developed with SuperSignal Pico Chemiluminescent Substrate (Thermo Fisher)
by combining SuperSignal ELISA Pico Stable Peroxide Solution, SuperSignal ELISA Pico
Luminol Enhancer, and CBB/0.1% BSA in a 1:1:8 ratio (v/v/v). Luminescence (in RLUs) was
measured by Luminoskan luminometer (Thermo Fisher). In the case of serum pools, sera at 1:400
dilution (in 1% BSA-PBS-T) was added to plates after blocking and incubated for 1 h at 37 oC.
After incubation, goat anti-human IgG (H+L) biotinylated antibody (Thermo Fisher) at 1:10,000
dilution in 1% BSA-PBS-T was added to plate and incubated for 1 h at 37 oC. After incubation,
CL-ELISA for serum pools was performed as described for biotinylated IB4 lectin.
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3.2.6 Immobilized lectin affinity chromatography (LAC) with Bandeiraea simplicifolia
isolectin 4 (IB4)-lectin for enrichment of a-Gal containing GPI-AP
a-Gal-containing GPI-AP were purified from the GPI-AP fraction by immunoaffinity
chromatography, using immobilized biotinylated IB4-lectin (Vector Labs) in streptavidin HP
SpinTrap (Cytiva) following the manufacture’s recommendation with minor modifications.
Briefly, storage solution was removed from the column at 150 g at 4° C for 1 minute. The column
was then equilibrated with 400 μl of 50 mM Tris/150 mM NaCl (TBS), at pH 7.5 centrifuged at
150 g at 4°C for 1 min three times. Then, 50 μg of IB4 were added to the column and incubated
overnight at 4°C slowly rocking. After incubation, free binding sites were blocked by adding 400
μl blocking buffer (2mM Biotin in TBS) and the column was incubated for 5 min at room
temperature for 5 min while rocking slowly. Column was then washed with TBS and centrifuged
at 150 g, 4°C for 1 min three times following by the addition of the GPI-AP sample into the
column. The sample was incubated overnight at 4°C, with slow rocking motion. After incubation,
unbound GPI-AP molecules (flow- through fraction, FT) were removed and collected by
centrifuging the column at 150 g at 4°C, for 1 min. The column was then washed with 400 μl wash
buffer (2 M urea in TBS, pH 7.5) and centrifuged at 150 g at 4°C for 1 min five times. Each wash
was collected, and pooled (Wash fraction, W) fractions were pooled and collected. Finally, the
column was eluted with 200 μl elution buffer (0.1 M glycine/2 M urea, pH 2.9) and centrifuged at
1,000 g, 4° C three times. Each elute was collected and pooled (elute fraction, EL, rich in α-gal
containing GPI-AP) and quickly neutralized with 1 M Tris, pH 8.0.
3.2.7 Hydrophobic interaction chromatography (HIC) with octyl-Sepharose (OS) column
FT, W and EL from immunoaffinity chromatography or GPI-AP directly from protein
extraction, both type of samples previously dried in a vacuum concentration, were further
fractionated and desalted by HIC using OS columns as previously described (59, 167, 168).
Briefly, OS columns were prepared by packing 2-cm of octyl-Sepharose CL-4B (Sigma-Aldrich)
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into 5 mL polypropylene columns with porous polyethylene stopper disc (Thermo Fisher). OS
packed column was wash with 3-column volumes of 70% PrOH containing 0.1 M NH4Ac in order
to remove any impurities and then equilibrated with 5-column volumes of buffer A (5% PrOH
containing 0.1 M NH4Ac). Dried samples were resuspended in buffer A and loaded into the OS
column. Sample flow-throughs were collected and loaded two more times into the OS column to
maximize sample binding. Bound samples were first desalted (salts left from buffers in
immunoaffinity chromatography) with 3-column volume washes of buffer A. Then, bound samples
were eluted from the OS column with 3-column volume washes of 30% PrOH containing 0.1 M
NH4Ac and collated (30% PrOH fraction) following by an elution with 3-column volume washes
of 60% PrOH containing 0.1 M NH4Ac and collated (60% PrOH fraction). All collected fractions
were dried in a SpeedVac (Thermo Fisher) vacuum concentrator, resuspended in water, and freezedried to remove traces of ammonium acetate.
3.2.8 a-galactosidase treatment
To test the specificity of IB4 in the GPI-AP fractions is due to a-gal epitopes, GPI-AP
fractions were treated with green coffee bean α-galactosidase (in ammonium sulfate suspension,
≥9 units/mg protein, Sigma-Aldrich) which cleaves a-gal epitopes. MaxiSorp Nunc polystyrene
96-well microplate wells were coated with GPI-AP fractions in CBC buffer and incubated O/N at
4 °C. The microplate free sites were blocked with 200 µL 1% BSA-PBS-T for 1 h at 37 °C, washed
three times with 200 µL PBS-T, and subsequently washed twice with 150 µL of 100 mM potassium
phosphate buffer (pH 6.5), to equilibrate the microplate to the appropriate pH before enzyme
addition. Then, the green coffee bean α-galactosidase was centrifuged at 10,000 g for 10 min at
4 °C to remove excess ammonium sulfate. The supernatant was discarded and the pellet containing
the enzyme was resuspended in ice-cold 100 mM potassium phosphate buffer (pH 6.5). 50 µL of
the enzyme solution (0.5 U/well) were added to each well, and the plate was incubated for 24 h at
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37 °C in a humid chamber. The microplate was washed twice with 200 µL PBS-T and CL-ELISA
was performed as described above.
3.2.9 Immunoblotting with IB4 lectin and serum from leishmaniasis patients
GPI-AP fractions were electrophorized by sodium dodecyl sulphate-polyacrylamide gel
electrophoresis (SDS-PAGE) using 4-20% Mini-PROTEIN® TGXTM Precast Protein Gel (BioRad) following the manufacture’s recommendation. Precision Plus ProteinTM Dual Color (BioRad) standard was included in each gel for molecular weight estimation. After electrophoresis,
proteins were transferred to polyvinylidene difluoride (PVDF, GenScript) membrane using
eBlotTM L1 (GenScript) wet transfer system following the manufacture’s protocol and buffers.
After transfer, membranes were blotted with biotinylated IB4. Briefly, membranes were blocked
with 1% bovine serum albumin/Tris buffered saline (50 mM Tris, 150 mM NaCl) with 0.1%
Tween 20 (1% BSA/TBS-T), pH 7.6 overnight at 4 °C. After incubation, membranes were washed
three times with TBS-T for 5 min (all washes in this method were performed as mentioned) and
incubated with 10 µg/mL of IB4 in 1% BSA/TBS-T for 1 h. After washing three times, membranes
were incubated with High Sensitivity NeutrAvidin-horseradish peroxidase at 1:5,000 dilution in
1% BSA/TBS-T for 1 h and membranes were developed by adding SuperSignal West Pico Plus
(Thermo Fisher) chemiluminescent substrate following the manufacture’s recommendation.
Images of the membrane were immediately taken after developing with iBright Western Blot
Imaging Systems (Thermo Scientific) and images were analyzed with iBright Analysis software
(Thermo Fisher). All steps after blocking were performed with gentle agitation at room
temperature. After blotting with IB4, membranes were stripped with RestoreTM Plus Western Blot
(Thermo Fisher) stripping buffer following the manufacture’s recommendation. After stripping
IB4 lectin, membrane was probed with leishmaniasis patient’s serum at 1:400 dilution in 1%
BSA/TBS-T for 1 h at 37 °C. Then, membrane was washed three times with TBS-T and incubated
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with goat anti-human IgG (H+L) biotinylated antibody at 1:10,000 dilution in 1% BSA/TBS-T for
1 h at 37 °C. Finally, membrane was developed and imaged as describe above.
3.2.11 Matrix-assisted laser desorption ionization time-of-flight (MALDI- TOF) mass
spectrometry
PrOH fractions will be analyzed by MALDI-TOF in negative mode on a Shimadzu 8020
MALDI-TOF. Matrix selection is still being discussed.
3.2.12 Mild acid hydrolysis
In order to remove P-linked glycans, freeze-dried PrOH fractions were treated with 50 µL
of 40 mM trifluoracetic acid (TFA) for 10 min at 100 °C. After hydrolysis, fractions were dried in
a SpeedVac vacuum concentrator.
3.2.13 Aqueous hydrogen fluoride dephosphorylation
GPI anchor and P-linked glycans were removed together by aqueous hydrogen fluoride
dephosphorylation. Freeze-dried PrOH fractions were treated with 50 µL of 48% hydrogen
fluoride (HF) for 48 h at 0 °C and dried in a SpeedVac vacuum concentrator. Fractions were then
dried twice from 50 µL of H2O to remove residual HF.
3.2.14 b-elimination of O-linked glycan
O-linked glycans were removed from dried PrOH fractions by b-elimination in a mild
alkaline treatment. Briefly, dried fractions were treated with 500 µL of 50 mM NaOH containing
1M NaBH2 and incubated at 45 °C for 16 h. After incubation, the reaction was neutralized with
10% acetic acid dropwise and desalted by ion exchange chromatography (1mL DOWEX 50X8100 column) and freeze-dried. Boric acid was removed with 500 µL of 5% acetic acid in methanol
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five times until borates were completely removed. Residual acetic acid was removed by coevaporation under nitrogen with 100 µL of toluene two times.
3.2.15 Peptide N-glycosidase F (PNGase F) digestion
N-linked glycans were removed from dried PrOH fractions by PNGase F digestion. Briefly,
dried fractions were boiled at 100 °C for 10 min in 16 µL H2O and then 2 µL of 0.25 M sodium
phosphate (pH 7.5) and 500 units of PNGase F (New England Labs) were added followed by
incubation at 37 °C for 16 h.
3.3 RESULTS
GPI-AP protein were extracted first from ~7x109 MP and PR (MP and PR were isolated
from each species as described in methods) of each parasite and the fractions from the 9% BuOH
were labeled as unpurified. Myo-inositol from these glycoproteins was quantified by GC-MS and
fractions were analyzed for α-Gal epitopes by CL-ELISA using 10 µg/mL IB4 and 100 pmol from
unpurified fractions (Figure 3.1). All species, both in PR and MP, had reactivity to IB4 as
compared to negative control 2ME-BSA. Interestingly, Lm Friedlin MP and Lb 1174 Cali PR had
the highest reactivity.
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Figure 3.1 Reactivity of IB4 lectin with unpurified (9%BuOH) MP and PR fraction
Unpurified fractions from Leishmania metacyclic promastigotes (MP) and promastigotes
(PR) obtained after glycoprotein extraction were analyzed by CL-ELISA with 10 µg/mL IB4
lectin. RLU, relative luminescence units. The results are means ± SD of three replicates.

Then, α-Gal containing GPI-AP were purified from unpurified fractions by LAC with
immobilized IB4. Three fractions were collected, FT, W and EL which contained the α-Gal
containing GPI-AP and myo-inositol content was quantified again as previously described here.
However, quantification was only possible for FT fractions because W and El contained high
amounts of salts making them unsuitable for GC instrumentation. To solve this problem (desalting
the sample), HIC-OS in a propanol gradient of 5, 30 and 60% was implemented. HIC-OS served
two functions, desalt (elute at 5% PrOH) and further fractioned the samples to separate GPI-AP
(elute between 10-30% PrOH) from any remining GIPL (elute between 30-60% PrOH) not
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separated during protein extraction. Quantification of these fractions are still being done.
Therefore, for the next set of experiments, only a percentage of total fraction from Lm Friedlin PR
and MP was used for the next set of experiments. The 30% PrOH fractions Lm Friedlin PR and
MP analyzed using an antigen titration per well from 10% to 0.62% of total fraction volume. EL
fractions, from both MP and PR, showed high reactivity to IB4 at 10% antigen concentration and
the reactivity decreases as the antigen concentration decreases too (Figure 3.2). These results
indicate the presence of GPI-AP with α-Gal epitopes in L. major in both stages, MP and PR.
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Figure 3.2 Reactivity of IB4 lectin with L. major MP and PR 20% PrOH fraction obtained by
HIC-OS after LAC a-gal enrichment.
30% PrOH Fractions from L. major metacyclic promastigotes (MP) and promastigotes
(PR) obtained by HIC-OS after LAC a-gal enrichment (FT: flow-through, W: wash, and EL: elute
fractions) were analyzed by CL-ELISA with 10 µg/mL IB4 lectin. The highest reactivity to a-gal
epitopes was shown in the EL fractions in both MP and PR. The antigen was titrated from 10% to
0.62% of total fraction volume. RLU, relative luminescence units. The results are means ± SD of
three replicates.
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30% PrOH fractions from L. major were further analyzed for the presence of a-gal
epitopes. Fractions were treated with 0.5 U of a-galactosidase which cleaves terminal a-gal.
Reactivity of treated and non-treated fractions to IB4 were analyzed by Cl-ELISA (Figure 3.3). As
expected, El fractions treated with a-galactosidase showed a reduction, 61% and 73% for MP and
PR respectively, of reactivity to IB4 as compared to non-treated El fractions. This indicate that in
fact, glycoproteins in the EL fractions contained true a-gal epitopes. Furthermore, 1 µg of each
fraction was used in SDS-PAGE to separate the glycoprotein by mass. Two SDS-PAGE gels were
run in parallel and used for silver staining and western blot to identify GPI-AP with a-gal epitopes.
Silver stained of the SDS gel revealed strong bands at approximately 30-33 kDa in W and EL in
MP sample, and El in PR sample with the distinctive smear-like band shape of glycoproteins
(Figure 3.4 A). The band in the W fraction could be the result of a-gal-containing GPI-AP not
bound to the IB4-streptavidin column during LAC, and thus, washed out and collected during the
wash step. For the western blot, after probing the SDS with IB4 and exposing it for 5 seconds, it
was noticed a strong band at approximately 30-33 kDa in EL in both MP and PR samples (Figure
3.4 B). The signal of these bands became more intense after increasing the exposure time to 40
seconds and a smaller band appeared in the W fraction (Figure 3.4 C). Furthermore, the same
western blot membrane was stripped with a stripping buffer and reprobed with an active cutaneous
leishmaniasis patient’s serum at 1:400 dilution (Figure 3.5). Interestingly, the same 30-33 kDa
band showed again indicating that the same glycoprotein that reacted with IB4 is reacting to the
serum pool.
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Figure 3.3 Reactivity of IB4 lectin and L. major MP and PR LAC a-gal enrichment fractions
following a-galactosidase treatment.
LAC a-gal enrichment fractions from L. major metacyclic promastigotes (MP) and
promastigotes (PR) (FT: flow-through, and EL: elute fractions) and unpurified fractions (9%
BuOH) were analyzed by CL-ELISA with 10 µg/mL IB4 lectin following a 16 h a-galactosidase
treatment. Reduction of 61%-89% of reactivity of EL from LAC a-gal enrichment fractions was
detected. Antigen concentration was used at 1% of total volume. RLU, relative luminescence units.
The results are means ± SD of three replicates
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Figure 3.4 Silver staining and immunoblotting with IB4 of L. major MP and PR 30% PrOH
fraction obtained by HIC-OS after LAC a-gal enrichment.
30% PrOH fractions from L. major metacyclic promastigotes (MP) and promastigotes (PR)
obtained by HIC-OS after LAC a-gal enrichment (FT: flow-through, W: wash, and EL: elute
fractions) were analyzed by (A) silver staining and western blot with 10 µg/mL IB4 lectin at (B) 5
sec exposure or (C) 40 sec exposures. A glycoprotein was detected at 30-33 kDa (red arrow) that
reacted strongly with IB4. 1 µg of each 30% PrOH fraction was used per line.
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Figure 3.5 Immunoblotting with an active cutaneous leishmaniasis patient’s serum at 1:400
dilution and L. major MP and PR 30% PrOH fraction obtained by HIC-OS after
LAC a-gal enrichment
30% PrOH fractions from L. major metacyclic promastigotes (MP) and promastigotes (PR)
obtained by HIC-OS after LAC a-gal enrichment (FT: flow-through, W: wash, and EL: elute
fractions) were analyzed by western blot with 1/400 active cutaneous leishmaniasis patient’s serum
40 sec exposure probing same the membrane from figure 3.4 A (stripped). The same glycoprotein
was detected at 33 kDa (red arrow) that reacted with the serum pool. 1 µg of each 30% PrOH
fraction was used per line.
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3.4 DISCUSSION AND FUTURE WORK
Currently, leishmaniasis is endemic in 90 countries, with an estimation worldwide of more
than 2 million cases annually and incidence of 350 million people at risk of infection. The broad
clinical spectrum of the leishmaniasis makes differential diagnosis, follow-up therapy evaluation
and clinical trials very difficult. Therefore, there is an urgent need for new diagnosis methods that
are discriminatory and that can be used for follow-up of leishmaniasis chemotherapy. Here, we
presented α-Gal containing GPI-AP that could potentially be used as biomarkers for the diagnosis
of leishmaniasis.
Bases on the preliminary data presented in this chapter, α-Gal containing GPI-AP were
found in samples from L. braziliensis, L. major, L. guyanensis and L. donovani. In L. major, a 3033 kDa α-Gal containing GPI-AP was found by western blot. However, the expected GPI-AP
could not be found by MALDI-TOF.
The study has presented several limitations that are currently being solved. One the
limitation is that we have not had enough starting parasite material to carry out all the required
experiments. To solve this, we have greatly expanded our parasite cultures to at least ~5x1010 as
starting material for protein extraction. Another limitation is the quantification of GPI-AP which
is needed to really know how much of each fraction we are using in each experiment. We have
tried BCA and A205 Scopes method. Each of these two methods have resulted very unreliable and
not consistent. Therefore, the proper method will be myo-inositol quantification by GS-MS that
has been optimized successfully. Finally, another limitation has been during mass spectrometry
either by MALDI-TOF or ES-MS/MS. The GPI-AP have resulted to be hard to digest
enzymatically for ES-MS/MS and hard to ionize by the matrix for MALDI-TOF. These limitations
are currently being solved by testing different enzymatic digestion and different matrixes in
addition to GPI-AP being treated (proposed in the methods section) with different methods to try
to remove the glycosylation and have better results. These procedures will be done by future lab
members.
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Chapter 4: Trypanosoma cruzi infection surveillance in triatomine vectors, feral dogs and
cats, and wild animals in and around El Paso, Texas and New Mexico

4.1 INTRODUCTION
The vector-borne parasite Trypanosoma cruzi causes Chagas disease. The parasite infects
many mammals including humans, domestic and wild animals in the Americas (68). An estimated
8 million people are infected in Latin America (171) and approximately 300,000 chronically
infected people live in the United States (172). The infection in humans and animals can be
asymptomatic or symptomatic, progressing from an acute phase with flu-like symptoms to a
chronic cardiac and/or gastrointestinal (GI) disease that can lead to heart failure, GI mega
syndromes and/or sudden death (68, 173, 174). There is no human or veterinarian vaccine, and
chemotherapy options are of limited efficacy, and exhibit frequent adverse events and variable
outcomes (175). Transmission to mammals occurs after the introduction of infected triatomine
fecal material into a wound or mucous membrane, as well as by the oral (consumption of foods
and juices contaminated with T. cruzi-infected kissing bugs or their feces), congenital, and/or
transfusion/transplantation routes (176). The nocturnal triatomine vector, also known as “kissing
bug”, serves as the main mode of transmission, particular in established sylvatic and domestic
transmission cycles (75). Around 100 different wildlife mammalian species are competent
reservoirs of T. cruzi (177) and at least 24 species have been recognized as natural wildlife
reservoirs in the United States (171), with canines being the most important component of
peridomestic transmission, forming a connection between sylvatic and domestic transmission
cycles (178, 179). Lastly, human infections can occur when triatomines establish nests near houses
and triatomines feed on both humans and animals (180).
There are 141 currently recognized triatomines species in the Americas, many of which
can be infected by and transmit T. cruzi (73). Of those, 11 species are native to the United States,
distributed across the southern half of the country from East to West (171). Seven of these species
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have been collected in Texas and all have the potential to transmit T. cruzi (181). Although
triatomines are an important source of human infections, canines are more likely to be infected
with T. cruzi than humans because of behavioral factors, such as the ingestion of the triatomines
by dogs that cause infection through the oral route and because canines commonly sleep outside,
increasing the chances of the vector feeding on them (177, 182-184). In Texas, the transmission
cycle includes seven reported triatomine species and 27 wild mammalian reservoirs, with many
more mammalian reservoirs potentially involved in the cycle (185). Finally, some human studies
in Texas have reported autochthonous transmission of T. cruzi to humans (186-190).
While there is increasing evidence of Chagas disease in Texas, epidemiologic assessment
studies on this disease have not been conducted in southwest Texas, which includes El Paso, an
urban border city with a population of over 830,000. Therefore, in this study, we evaluated the
prevalence of T. cruzi in wild triatomines, and peridomestic stray or feral dogs and cats, and wild
animals in El Paso and surrounding communities. All T. cruzi positive samples were further
characterized to determine the genotype or discrete typing units (DTU) of the parasite, an
important genetic marker, as well as the mammalian source of the bloodmeals for triatomines. An
understanding of the prevalence, distribution, and genetic profile of T. cruzi in triatomines, and
feral and wild animals provided an estimate of the disease risk in both peridomestic and rural
settings. Bloodmeal analysis provided critical information on the components of transmission
cycles in El Paso area and surrounding areas, as well as transmissibility risks.
4.2 MATERIALS AND METHODS
4.2.1 Ethics statement
The blood and tissue samples from peridomestic, feral dogs and cats, and wild animals
were collected by the veterinarian of the Texas Department of State Health Services, Zoonosis
Control Region 10 in the El Paso and surrounding urban and rural communities. The samples from
dogs and cats were obtained from a local animal shelter and coordinates of capture location were
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provided according to the approved protocols A-201408-1, and by the UTEP’s Institutional
Animal Care and Use Committee (IACUC) and Institutional Biosafety Committee (IBC) protocol
numbers 2014-04, 1608423, and 1111061-1.
4.2.2 Triatomine collection, identification, and DNA extraction
Triatomine insects were collected from May 2016 to September 2019 (between May and
September of each year) in peridomestic and rural areas in El Paso County and Indio Mountains
Research Station (IMRS) in Hudspeth, Texas. Collections were also carried out in the urban
communities of Anthony and Las Cruces, New Mexico (Figure 1). El Paso is an urban city located
in the far southwestern part of Texas bordering Mexico. El Paso city has a population of 681,728,
while El Paso County has a population of 839,238, in close proximity to two urban communities,
the cities of Las Cruces and Anthony, both in Doña Ana County, NM. Las Cruces is located 45
miles northwest of El Paso with a population of 103,432. Anthony is located 18 miles northwest
of El Paso with a population of 9,239. The other collection site, IMRS, is located 26 miles
southwest of Van Horn, TX (121 miles from El Paso). IMRS has no permanent residents and is
used as a field research station by UTEP and as a camping site. Previously, we reported the
prevalence of T. cruzi in IMRS (191). The triatomine species were identified morphologically
(192) and by PCR (193). Insects were collected by our laboratory members using black light vane
trap (BioQuip, Rancho Dominguez, CA), and by hand collection using tweezers (194, 195), and
by members of the communities by unreported ad hoc methods (e.g., household items such as cups,
pans, plastic bags, etc.). A total of 225 triatomines were captured; 212 were preserved in 95%
ethanol, whereas 13 were stored directly at -20oC until analysis. All insects were rinsed in a 1%
sodium hypochlorite solution and dissected using sterile instruments in a class-II biosafety cabinet
(196). Dissection was done by carefully removing both pairs of wings, cutting off the connexivum
to finally lift up the abdominal wall to reveal the hindgut. The triatomine hindgut was homogenized
with a cordless pestle motor (Kimble) in 40 µL phosphate-buffered saline (PBS), pH 7.4. DNA
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extraction of all samples were done with High Pure PCR Template Preparation Kit (Roche) using
the manufacturer’s recommendation. The triatomine genetic material was used to identify the
insect species by sequencing a PCR amplification product of mitochondrial DNA, as previously
described (193). Maps were generated with Maptitude 2019 (Caliper Software, Newton, MA) and
DIVA-GIS 7.5 (https://www.diva-gis.org/).
4.2.3 Detection of T. cruzi in triatomine samples
The samples of triatomine hindguts were tested for T. cruzi genomic DNA by PCR
amplification of a kinetoplastid DNA minicircle, as previously described with minor modifications
(197).

Reactions

consisted

of

200

ng

of

AAATAATGTACGGG(T/G)GAGATGCATGA-3’)

DNA

sample,
and

primers
122

121

(5’(5’

GGTCGATTGGGGTTGGTGTAATATA-3’ at final concentration of 0.4 µM each, 12.5 µM 2X
GoTaq Green Master Mix (Promega), and nuclease-free water to a final volume of 25 µL.
Reactions were run in a 9902 Veriti PCR Thermal Cycler (Applied Biosystems), using the
following conditions: incubation at 94°C for 3 min, followed by 35 cycles of 94°C for 30 sec, 57°C
for 30 sec, and 72°C for 30 sec. Final extension at 72°C for 7 min and end with at 4°C hold. T.
cruzi (Dm28c clone) genomic DNA positive control was run in all PCR reactions. A positive result
was determined by visualization of 330 bp band on a 2% agarose gel. The faint bands were
reamplified; the PCR reactions were run again with a double concentration of genomic DNA and
the PCR products that showed a very wide band (smear-like) were repeated diluting the amount of
DNA to half. The homogeneity in T. cruzi detection (i.e., equal proportion of positive outcomes in
the PCR reactions) among the 4 locations was tested with a χ2 test, setting α=0.05. The positive
ratios in each location were compared using Cohen’s D effect size (198).
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4.2.4 Triatomine bloodmeal analysis
T. cruzi-positive triatomine samples were analyzed to determine the mammalian species
on which they fed. Amplification of the 16S rDNA was accomplished by hemi-nested PCR, as
previously described (199) with minor modifications. The first reaction contained 3 µL of DNA
template from triatomine, a universal forward primer (VF) (ACC CNT CYM TGT NGC AAA
AKR GTG) and a mammalian group-specific forward primer (MF) (CCT GTT TAC CAA AAA
CAT CAC) at 0.25 µM final concentration, 12.5 µL 2X GoTaq Green Master mix, and nucleasefree water to a final volume of 25 µL. The secondary reaction contained 2 µL of the primary PCR
product, mammalian group-specific reverse primer (MR) (AYT GTC GAT AKG RAC TCT WRA
RTA) and MF at 0.5 µM final concentration, 12.5 µL 2X GoTaq Green Master mix, and nucleasefree water to a final volume of 25 µL. A positive triatomine control fed previously with rabbit
blood was used in all reactions. Subsequent bi-directional sequencing was run on an ABI
3130x/Genetic analyzer using Bid Dye Terminator chemistries (Applied Biosystems), following
the manufacture’s recommendation. Complementary sequences were assembled and verified using
CodonCode Aligner V 9.0.1 (CodonCode Corporation, Centerville, MA). Consensus sequences
were compared with DNA nucleotide sequences in NCBI BLAST, using the blastn query. Query
results with maximum identity equal to or higher than 95% and Expect (E)value equal to or lower
than 0 were considered matches. Positive species hits were confirmed to be present in El Paso and
surrounding areas based on species distribution using biodiversity databases (200, 201). A total of
41 samples presented mixed template sequencing traces that overlapped, making it impossible to
use them. This is because it is known that triatomines may contain DNA from more than one
mammalian bloodmeal. To resolve this, restriction enzymes were used for restriction fragment
length polymorphism (RFLP) analysis, as described previously (199). PCR products were singly
or doubly digested with Anza 68 BsuRI and/or Anza 44 AluI (Invitrogen) for 15 min, at 37°C, in
a reaction containing 10 U of each enzyme, 1X Anza buffer, 2 µL PCR product and nuclease-free
water to a final volume of 20 µL. Enzymes were heat-inactivated at 80°C for 20 min prior to
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electrophoresis. Products were electrophoresed in a 1.5% agarose gel and visualized with iBright
FL1500 imaging system (Thermo Fisher Scientific). Band sizes were estimated using iBright
imaging software (Thermo Fisher Scientific) and values compared to controls of the most common
mammals found during DNA sequencing (human, rat, mouse, dog, bat, cat, rabbit, horse, and
squirrel) and to values previously published (199). The Shannon-Wiener Index was calculated to
compare the bloodmeal diversity at each site, as higher values suggested higher diversity in the
site (202, 203), considering only those species confirmed as described above.
4.2.5 Feral and wild mammal sample collection and DNA extraction
The blood samples from feral or stray dogs and cats were collected from a local animal
shelter. Each sample had capture location coordinates determined by GPS. Wild rodents were
collected at the Hitt Canyon in the Franklin Mountains State Park in El Paso, TX, using baited
Sherman and tomahawk traps. Trapped rodents were identified to species (192), euthanized at the
site and the hearts were harvested for analysis. Heart tissues (20-30 mg) were homogenized using
gentleMACS M tubes and gentleMACS dissociator (Miltenyi Biotec) in 200 µL PBS. DNA was
extracted and each sample was subject to T. cruzi detection, as described above.
4.2.6 T. cruzi DTU determination
All T. cruzi positive samples were subjected to additional reactions to determine the
infecting parasite DTU by multilocus conventional PCR, as previously described (204). This
method was based on the amplification of different T. cruzi targets. The PCR targets were the
following: the intergenic region of Spliced Leader (SL-IRac) to distinguish between TcI (150 bp),
TcII, TcV and TcVI (157bp), and TcIII and TcIV (200bp) using primers UTCC
(CGTACCAATATAGTACAGAAACTG) and TCac (CTCCCCAGTGTGGCCTGGG). The SLIR I-II target to differentiate TcI (350 bp) from TcII, TcV and TcVI (300 bp) using primers TCC
(CCCCCCTCCCAGGCCACACTG), TC1 (GTGTCCGCCACCTCCTTCGGGCC) and TC2
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(CCTGCAGGCACACGTGTGTGTG). The D7 domain of the 24Sα ribosomal DNA target to
distinguish between TcII, TcIV and TcVI (140 bp), and TcIII and TcV (125 bp) in a heminested
PCR
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and
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and

D71

(AAGGTGCGTCGACAGTGTGG) (second round). Moreover, the A10 nuclear fragment target
to differentiate TcII (580 bp) from TcVI (525 bp) in a heminested PCR using primers Pr1
(CCGCTAAGCAGTTCTGTCCATA) and P6 (GTGATCGCAGGAAACGTGA) (first round)
and Pr1 and Pr3M (CGTGGCATGGGGTAATAAAGCA) (second round). The control PCR
reactions were performed with 100 pg gDNA extracted from T. cruzi: Dm28c (TcI), Y (TcII),
INPA 3663 (TcIII), CanIII (TcIV), LL014 (TcV), and CL Brener (TcVI). If a sample showed more
than one expected band, the presence of more than one infecting parasite DTU was considered,
and the sample was genotyped as a mix infection.
4.3 RESULTS
4.3.1 Triatomines collected and T. cruzi prevalence
A total of 225 triatomines were collected from four different sites, including 21 in El Paso,
TX, 33 at IMRS, TX, 139 in Anthony, NM, and 32 in Las Cruces, NM (Figure 4.1; Table 4.1).
The most common (98.2%, 221/225) species collected was Triatoma rubida across all sites of this
species, followed by Triatoma gerstaeckeri and Triatoma protracta (both 0.9%, 2/225), which
were both collected in El Paso (Table 4.1). A total of 150 (66.7%) triatomine samples were positive
for T. cruzi by PCR (Table 4.1), and of those 147 were T. rubida, two T. gerstaeckeri, and one T.
protracta. The prevalence rate of T. cruzi in triatomines varied along collection locations (χ2 =
12.8653, p = 0.002) as follow: Las Cruces, NM (27/32, 84.4%), IMRS (24/33, 72.7%), Anthony,
NM (91/139, 65.5%) and El Paso, TX, (5/17, 29.4%) (Table 4.1). Cohen’s D effect size identified
El Paso as having a lower prevalence rate than all other locations (Cohen’s D large effect size
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>0.5) and Anthony as having a lower prevalence rate than Las Cruces (Cohen’s D medium effect
size >0.3).

Figure 4.1. Sample collection sites in El Paso County and surrounding areas in Texas and New
Mexico.
(A) Major triatomine collection sites in or nearby El Paso County (blue circle) and at IRMS, TX
(yellow triangle). (B) Detailed location and map of IMRS, TX. Inset: IRMS laboratory (encircled
black dot) and the field station entire area (white line) are indicated. (C) Detailed map of
distribution of collected samples in El Paso County, TX, and nearby areas in New Mexico (cities
Anthony and Las Cruces).
Table 4.1 T. cruzi-positive triatomines and DTU genotyping of triatomines collected in the El
Paso County, TX, and surrounding rural and urban communities in Texas and New
Mexico.
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a

P/T, Positive for T. cruzi per total number of triatomines collected

b

ND, Not determined

c

Found in Hueco Tanks, near El Paso, TX

4.3.2 Triatomine bloodmeal analysis
The bloodmeal source was identified in 65.3% (98/150) of the T. cruzi-positive triatomines
collected at three different sites, using two methodologies (DNA sequencing, n = 57, and RFLP, n
= 41) (Table 4.2). Thirteen different mammalian host species were identified. The majority (n =
95; 96.9%) of bloodmeal sources were identified from T. rubida, one from T. protracta, and two
from T. gerstaeckeri (Table 4.2). Furthermore, by bloodmeal DNA sequencing, we found that one
of the T. protracta specimens collected in El Paso, TX, contained a single bloodmeal from Mus
musculus, whereas by RFLP we observed that two T. gerstaeckeri specimens shared a mixed
bloodmeal of dog (Canis sp.) and mouse (Mus sp.). However, unfortunately, we were unable to
determine the species of the latter. The greatest blood feeding diversity was detected in Anthony,
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NM, where 11 different host species served as a source of blood and the value for the ShannonWeiner Index was 1.67, higher than the values 1.34 and 0.90 found in IMRS and El Paso,
respectively. The most frequently host species fed upon by triatomines in El Paso and Anthony
was the house mouse, while woodrats were the most frequently preferred host in IMRS.
Interestingly, humans were identified as a source of blood for triatomines in Anthony and IMRS
(n=7 and n=3, respectively). Canid blood was also commonly found in triatomines collected in El
Paso and Anthony (n=4 and n=10, respectively) (Table 4.2). The source of blood for 25 triatomines
could not be identified by either of the two methods used in this study.
Table 4.2 Identification of mammalian host species that served as a bloodmeal source for T.
cruzi-infected triatomines in El Paso and IMRS, TX, and Anthony, NM, identified
by DNA sequencing and RFLP analysis.

a

This analysis was done based on the fragment size of the double-digestion with BsuRI and AluI

of the 16S rDNA fragment obtained by PCR, and compared with already known sequences
obtained here, and published data. Based on this analysis, most of the digestion fragments had very
close molecular sizes, which impaired the identification of the animal species.
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b, c

Out of the 98 bloodmeals listed in the table, 95 were identified from T. rubida, one from T.

protracta (b), and two from T. gerstaeckeri (c).
4.3.3 T. cruzi infection in feral cats and dogs, and wild animals
A total of 95 and 24 blood samples were collected from feral canines and felines,
respectively, within the El Paso urban area (Table 4.3). Among these samples, 45.3% (43/95) of
the dogs and 29.2% of the cats (7/24) were positive for T. cruzi by PCR (Table 4.3). Additionally,
at the Hitt Canyon of the Franklin Mountains State Park, located in El Paso, TX, a total of seven
wild animals’ heart samples were collected from two Chaetodipus intermedius, and one each of
Peromyscus eremicus, Xerospermophilus spilosoma, Reithrodontomys megalotis, Urocyon
cinereoargenteus, and Canis latrans. When analyzed for T. cruzi infection by PCR, all but two
from C. intermedius (rock pocket mouse) were positive for T. cruzi (Table 4.4).
Table 4.3 Prevalence of T. cruzi infections and DTU genotyping in feral or stray dogs and cats
collected in El Paso County, TX.

a

P/T, Positive for T. cruzi per total number of triatomines collected

b

ND, Not determined
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Table 4.4 Prevalence of T. cruzi infection and DTU genotyping in wild animals collected at Hitt
Canyon, El Paso County, TX.

a

NA, not applicable

4.3.4 T. cruzi DTUs genotyping
Among all of the T. cruzi-infected triatomines, and feral and wild animals, the parasite was
successfully genotyped in 95.1% of the samples (195/205; Tables 4.1, 4.3, and 4.4). Of the total
150 T. cruzi-positive triatomines, genotyping revealed that 138 were DTU TcI across all sites,
seven from El Paso, 22 from IMRS, 84 from Anthony, and 25 from Las Cruces (Table 4.1). In
addition, two triatomines, one from IMRS and one from Anthony, showed TcIV infection. The
genotyping also revealed that seven triatomines had mixed TcI and TcIV (TcI+TcIV) infection
(five from Anthony and two from Las Cruces) (Table 4.1). In the case of feral dogs in El Paso
area, TcI was found in 30 animals. TcIV was found in nine canines and only one canine was found
to have a mixed TcI+TcIV infection. In felines, TcI was found in two animals and TcIV in one
animal (Table 4.3). Finally, in the wild animals, TcI infection was found in three animals (R.
megalotis, U. cinereoargenteus and C. latrans) and two TcI+TcIV mixed infection were found in
two animals (P. eremicus and X. spilosoma) (Table 4.4).
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4.4 DISCUSSION AND FUTURE WORK
The prevalence of T. cruzi infection in humans and animals in the U.S. has been recently
more studied, since it has become an emerging public health threat in the southeast and southwest
regions (83, 177, 183, 186, 189, 190, 205-209). In this study, triatomines and blood samples from
feral or stray dogs and cats, and wild animals were collected at four different sites in El Paso
County and surrounding areas in TX and NM. These samples were tested for T. cruzi infection,
and positive samples were genotyped to determine parasite DTUs. Moreover, triatomine
bloodmeal analysis was performed on T. cruzi-positive samples to identify mammalian host
species. This is the first study that determined the prevalence of T. cruzi infection in El Paso
County (839,238 inhabitants, 2019) and surrounding areas in Texas and New Mexico. It is
important to highlight that this study also identified the species of regional triatomines, determined
the T. cruzi infection rates in feral and wild animals, genotyped infecting T. cruzi parasites, and
characterized the triatomine bloodmeals, therefore identifying other potential reservoirs of the
parasite.
Three different species of triatomines were collected during this study. T. rubida was the
most common species, followed by two species with similar low frequency rate of capture, T.
gerstaeckeri and T. protracta. These two species with low frequency collection rates were captured
at sites in an area named Hueco Tanks, a low rocky mountain rural community located in far east
El Paso and worldwide well-known climbing and bouldering site, visited by hundreds of people
every year (Fig. 4.1). T. gerstaeckeri is the most frequently collected species in the U.S., mostly
found in southeastern Texas, with a cumulative T. cruzi infection rate of 57.7%, while T. protracta
has been reported in California, Arizona, New Mexico, and the southern border of Texas with
Mexico, with an overall T. cruzi infection rate of 17.5% (171). In the case of T. rubida, this species
has been found from western Texas to southern California with a very low cumulative infection
rate of 7.2 % (much lower rate than what was found in this study) (171). The present study is the
first to report the presence of T. gerstaeckeri and T. protracta in El Paso County and surrounding
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areas. In the case of T. rubida, a few specimens have been reported since 1949 in El Paso as well
as in Ciudad Juarez, a city across the border in Mexico (83, 171, 210, 211). The only other
Triatoma sp. reported in El Paso is Triatoma indictiva, but no infection status or the exact
collection location was available (171). As for Las Cruces and Anthony, NM, T. protracta and T.
rubida have been reported, but these reports belong to the Doña Ana County, where these two
cities are located, and no exact location has been reported (171). Here, T. rubida was also the only
species found at IMRS, which is the same species reported by our group in 2015, when 39 T.
rubida specimens were identified (191). Studies on the biology behavior and spatial distribution
of T. rubida, the most frequently collected species in this study, indicated that this species inhabits
environments in close association with their hosts, which includes wild and domestic animals, as
well as humans and they are extremely attracted to host-emitted cues, such as body odors, CO2,
moisture and heat as well as light sources (171, 206, 212-215). All of these factors can be found
in human residences. Remarkably, all residence locations where triatomines were collected were
within the limits of the city of El Paso, next to mountains in semi-rural areas. Furthermore, in El
Paso, all residences had domestic dogs and the residents found the triatomines in close proximity
to where their dogs slept. It has been reported that dogs are a risk factor for triatomine occurrence
in residences forming a transmission bridge for T. cruzi between human and infected dogs(177,
182, 183, 216). Thus, a possible explanation for the prevalence of triatomine among residences
within city limits of El Paso is that triatomines are attracted to dogs, humans, and light sources.
This is also corroborated for triatomines collected from Anthony and Las Cruces, NM, which were
collected around lights located in porches and outside buildings. Additionally, studies about the
feeding and defecation behavior of T. rubida indicated this species as an efficient vector (212).
This is because T. rubida defecates while taking a bloodmeal and it has been proposed that
triatomine species that defecate sooner than ten minutes after taking a bloodmeal are effective T.
cruzi transmitter, such as the case for T. rubida (212, 217-219). These findings suggest T. rubida
poses a transmission risk of T. cruzi in El Paso County and surrounding areas, based on
distribution, habitat, and feeding behavior.
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Of the 225 triatomines collected and analyzed, 150 (66.7%) were positive for T. cruzi. This
infection rate was within the range reported during similar studies conducted in the southern region
of the U.S. (range from 41.5 to 80.6% in studies in Texas, Louisiana, and Arizona) (177, 179, 183,
191, 206, 220-224). While it is not possible to quantitatively compare infections rates among
locations that were sampled using different methodologies, the potential biases resulting from such
differences can be inferred to be small enough to allow qualitative comparisons (225). In this study,
Las Cruces, NM, had the highest infection rate (84.4%), which was higher than rates published
previously in the southwest, followed by Anthony, NM (65.5%). Interestingly, there has not been
any published studies of this nature in New Mexico, even though triatomines have been widely
reported in that state (171). El Paso County had the lowest infection rate of triatomines (8/21,
38.1%) (Table 4.1). While there is no clear explanation for the lower rate found in El Paso, it is
possible that the small number of samples obtained in this location is preventing an accurate
estimation of the infection rate. It is possible that the collection of more samples in the future will
allow for a more robust estimation of the prevalence rate. Finally, the infection rate at IMRS
(72.7%) was higher (15.4% increase) than that reported by our group in the same area in 2015
(191). These findings demonstrate an active presence of T. cruzi in triatomines collected in and
around El Paso County, TX.
Triatomines are obligate hematophagous and they can feed on any animal, but only
mammals are susceptible to T. cruzi infection (226). In our study, we used a methodology that
allowed for the identification of mammalian host species as the source of triatomine bloodmeals.
We only focused on the T. cruzi-infected insects for the purpose of linking infected triatomines
with possible hosts that could have been infected by the insect. Therefore, the mammalian species
source of bloodmeals were identified for 98 (79.7%) out of 123 T. cruzi-positive triatomines
collected in residences or in the wild, and immediately immersed in 95% ethanol or frozen until
processing. Twenty-seven triatomines from Las Cruces were not taken into consideration for the
bloodmeal analysis (Table 4.2) because they were kept alive in the lab by feeding them rabbit
blood. Our first approach detected single bloodmeals in 57 triatomine samples by DNA
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sequencing. Forty-one triatomine samples resulted in unreadable sequences that contain
overlapping base reads (Table 4.2). This is because it is known that triatomines may contain DNA
from more than one mammalian species (179, 199, 227). Thus, we opted for a second approach to
analyze the DNA by restriction fragment length polymorphism (RFLP) analysis (199). By using
this method, the mammalian blood source from the 41 aforementioned triatomines, was identified.
Finally, failure in the identification of the mammalian bloodmeal source in 25 triatomine samples
by both PCR and RFLP analysis could be attributed to: (i) triatomines feeding on non-mammalian
hosts such as birds, thus non-amplifiable in the 16S rDNA mammal-specific PCR reaction; or (ii)
the lack of a recent bloodmeal, allowing for a degree of blood degradation products inside the
insects’ midgut that made the identification by RFLP unfeasible, as previously reported (228-231).
The most diverse source of host bloodmeal were found in Anthony, where triatomine fed on 11
different species of mammals and a higher Shannon-Wiener Index in contrast to El Paso and IMRS,
where triatomines fed on 3 and 5 different species, respectively. This may be explained by the fact
that Anthony is a semi-rural city with the greatest mammal diversity compared to the other sites.
Among the most important results, humans were identified as the source of blood for 7 and 3
triatomines in Anthony and IMRS, respectively, raising the concern for the risk of Chagas disease
transmission in these localities, especially at IMRS which is used as a camping and biology field
station site. Of all locations, only in El Paso have there been reported cases of T. cruzi-positive in
blood donors, but no cases of autochthonous transmission have been reported (232). Moreover,
domestic dog, domestic cat, and house mouse were found to be a source of blood for triatomines.
These animals are important because they live near humans and extensive studies have shown that
these animals pose a risk as a source for possible human infection (233, 234). These findings
present evidence for potential vector-borne transmission of Chagas disease for humans as well as
domestic animals in El Paso County and surrounding areas.
Stray or feral domestic dogs and cats, and wild animals were also tested for T. cruzi.
Domestic dogs are considered as an important reservoir for T. cruzi in Latin America (184, 233,
235-243). It has been proposed that dogs are more likely to acquire T. cruzi infection due to
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ingestion of infected triatomines, thus allowing for oral transmission, and that dogs usually sleep
outside, increasing therefore the chances of triatomine contact (177, 178, 184, 209, 216, 244).
Moreover, infection in dogs has been reported from several southern states, including Texas and
New Mexico (205, 209). Another animal that lives in close contact with humans are cats. They
have been identified as potential sentinels for many infectious diseases because of the
environments they share with humans (207). However, the role of cats in relation to the
maintenance and transmissibility of T. cruzi has not been extensively studied and is not fully
understood; the very few studies conducted found a very low prevalence of infection (208, 245248). In this study, 45.3% (43/95) of feral dogs sampled were positive for T. cruzi, while 29.2%
(7/24) of the feral cats were positive for the parasite (Table 4.3). Samples from dogs and cats were
collected from all over the inner city of El Paso. Furthermore, 71.4% (5/7) of the wild animals
tested were positive for T. cruzi, thus suggesting an important reservoir role. All of the positive
species have been previously reported in Texas as T. cruzi reservoirs (249-252). Interestingly,
triatomine traps were set at sites where T. cruzi-positive feral dogs and cats, and wild animals were
captured, but attempts to collect triatomine at these sites were not successful. This might indicate
that the infection in these animals was acquired congenitally. One of the limitations of this part of
the study was that data for the age of animals was not available. Such data would have allowed us
to analyze the odds of an animal being infected congenitally or through vector transmission, since
older animals have a longer opportunity to be exposed to the vector(183, 253). These findings and
the substantial number of reported cases (dogs and cats) in Texas and New Mexico discussed in
this study may indicate that Chagas disease may occur among feral dogs and cats in the region and
that a transmission cycle between vector and animals may have already been established in the
western part of Texas.
Finally, the DTUs of all T. cruzi-positive samples were genotyped with a successful rate
of 95.1%. DTUs are important markers for clinical, ecological, and epidemiological features and
range from TcI to TcVI and TcBat (254). Here, TcI was the most predominant genotype, followed
by TcIV and some T. cruzi had a mixed TcI+TcIV infection. Among feral dogs and cats, the equal
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distribution of DTUs confirmed that there was no difference among them as hosts. TcI is found
throughout the Americas with domestic and sylvatic transmission cycles, and it’s associated with
chronic Chagas cardiomyopathy (255, 256). The finding that the most predominant DTU was TcI
is an alarming public health concern since chronic Chagas disease is the most challenging form of
the disease to be diagnosed and the harder to treat, with possible irreversible hearth damage (257259). On the other hand, TcIV is more involved in sylvatic transmission cycles in northern part of
South America and the USA, but its clinical association is not well understood and its risk to
humans is unknown (260). These findings are consistent with the documented DTU
characterization of T. cruzi across Texas and USA, where both DTUs have been reported in
humans and an extensive range of mammalian species (171, 261).
The rates and the observations that T. cruzi infection rates ranged from moderate to high
level in domestic and wild animals support an active enzootic/endemic transmission cycle in the
El Paso and surrounding communities. The observation that the most collected triatomine
specimens were T. rubida, which is considered an efficient vector, and the most observed DTU
was TcI, which is causative of the very harmful chronic Chagas cardiomyopathy, indicates a high
health risk for these communities that needs to be taken into consideration by the respective health
authorities. Additionally, the finding of human, canine and feline bloodmeals in these triatomines
suggests the possibility of autochthonous parasite transmission in humans as well as in
peridomestic or feral animals in the studied areas. More extensive studies are needed, particularly
in the high-populated El Paso County area to better understand the involvement of humans and
feral and wild animals in the transmission cycle as well as in the burden of Chagas disease.
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Chapter 5: Overview and final conclusions
The focus of this dissertation was to describe the anti-leishmanial activity of two types of
compounds, thiophene derivatives and methionine aminopeptidase 1 (MetAP1 inhibitors), for the
treatment of cutaneous leishmaniasis. The first class of compounds, thiophene derivatives, the
molecule 5D showed the highest in vitro activity against Leishmania major promastigotes (EC50
0.09 ± 0.02 μM), with an inhibition of the proliferation of intracellular amastigotes higher than
75% at only 0.63 μM and an excellent selective index. Moreover, the effect of 5D on L. major
promastigotes was associated with generation of reactive oxygen species (ROS), and in silico
docking studies suggested that 5D may play a role in inhibiting trypanothione reductase. The
second class of compounds, MetAP1 inhibitors, three compounds, OJT006, OJT007, and OJT008,
demonstrated potent antiproliferative effects in macrophages infected with L. major amastigotes
and promastigotes at submicromolar concentrations, with no cytotoxicity against host cells.
Importantly, the activity of these inhibitors was showed that they were acting on target, on MetAP1
from L. major . Furthermore, the in vivo activity of OJT008 was investigated in L. major-infected
BALB/c mice. In comparison to the footpad parasite load in the control group, OJT008 decreased
the footpad parasite load significantly, by 86%, and exhibited no toxicity in treated mice. Taking
together these results, we proposed 5D and OJT008 to be considered as a future approached for
the treatment of CL.
The second part, we aim to identify and characterized glycosylphosphatidylinositolanchored proteins (GPI-AP) that display highly immunogenic terminal nonreducing αgalactopyranosyl (α-Gal)- containing glycotopes that can be used as biomarker and vaccine
candidates. Here, GPI-AP from promastigotes (PR) and metacyclic promastigotes (MP) of L.
major, L. braziliensis and L. guyanensis, and L. donovani which cause CL, MCL and VL
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respectively were analyzed for the presence of α-Gal containing GPI-AP. Results indicated the
presence of α-Gal containing GPI-AP in L. major, L. braziliensis, L. guyanensis and L. donovani
in both stages, PR and MP. A 33 kDa glycoprotein was found by western blot probed with IB4
and serum from CL patients. Further analysis is needed to fully characterize α -gal containing GPIAP in each Leishmania sample and to be tested as biomarkers for the different clinical. In addition,
the 33 kDa glycoprotein needs to be further characterized by mass spectrometry.
Finally, it is understandable that vector control is another approach to control neglected
infectious diseases. Therefore, for the third and final part of this study, vector surveillance and
epidemiology were implemented in the Southwestern region of U.S. where epidemiological studies
are limited. We have determined the prevalence of T. cruzi in triatomines, feral cats and dogs, and
wild animals, as well as the infecting parasite genotypes and the mammalian host bloodmeal
sources of the triatomines at four different geographical sites in the U.S.-Mexico border, including
El Paso County, Texas, and nearby cities in New Mexico. Over 95% of T. cruzi of DTUs identified
were TcI and some TcIV. Furthermore, Triatoma rubida was the triatomine species most collected
in all samples analyzed. Therefore, our results clearly demonstrate the need for implementation of
a systematic epidemiological surveillance program for T. cruzi in United States that will improve
the prevention of Chagas disease.
Overall, the results from this dissertation provide novel insights and possibilities against
leishmaniasis and Chagas disease. The knowledge accumulated through these studies may
eventually result in the development of effective strategies for the treatment, diagnosis and
prevention against these parasites.
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